

537976

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



09 JUN 2005



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052925 A2

(51) International Patent Classification⁷: **C07K 14/195**

(21) International Application Number:
PCT/GB2003/005349

(22) International Filing Date: 8 December 2003 (08.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0228691.2 9 December 2002 (09.12.2002) GB

(71) Applicant (*for all designated States except US*): **IMPERIAL COLLEGE INNOVATIONS LIMITED** [GB/GB]; Electrical and Electronic Engineering Building, Imperial College London, Exhibition Road, London SW7 2AZ (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KROLL, John, Simon** [GB/GB]; Imperial College Innovations Limited, Electrical and Electronic Engineering Building, Imperial College London, Exhibition Road, London SW7 2AZ (GB). **LANGFORD, Paul, Richard** [GB/GB]; Imperial College Innovations Limited, Electrical and Electronic Engineering Building, Imperial College London, Exhibition Road, London SW7 2AZ (GB). **BOSSE, Janine** [CA/CA]; Imperial College Innovations Limited, Electrical and Electronic Engineering Building, Imperial College London, Exhibition Road, London SW7 2AZ (GB). **BEDDEK, Amanda** [GB/GB]; Imperial College Innovations Limited, Electrical and Electronic Engineering Building, Imperial College London, Exhibition Road, London SW7 2AZ

(GB). **RYCROFT, Andrew** [GB/GB]; Imperial College Innovations Limited, Electrical and Electronic Engineering Building, Imperial College London, Exhibition Road, London SW7 2AZ (GB). **SHEEHAN, Brian** [IE/IE]; Imperial College Innovations Limited, Electrical and Electronic Engineering Building, Imperial College London, Exhibition Road, London SW7 2AZ (GB).

(74) Agents: **MACLEAN, Martin, Robert et al.**; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BACTERIAL VIRULENCE GENES

(57) Abstract: An attenuated *Actinobacillus pleuropneumoniae* bacterium has a mutation in a gene required for bacterial virulence. Vaccines based upon the bacterium are provided, as are isolated virulence genes and polypeptides and uses thereof.

WO 2004/052925 A2

BACTERIAL VIRULENCE GENES

The present invention relates to the identification of genes involved in the virulence of *Actinobacillus pleuropneumoniae*, to the production of attenuated mutant strains
5 of *Actinobacillus pleuropneumoniae*, and to the identification of anti-bacterial agents which target the identified genes and their products.

A. pleuropneumoniae is the causative agent of porcine pleuropneumonia, a highly contagious, respiratory disease of pigs. The disease is often fatal and as a result
10 leads to severe economic loss in the swine producing industry. An obligate parasite of the porcine respiratory tract, the incidence of infection of *A. pleuropneumoniae* has increased in recent years, notably where animals are subjected to intensive breeding conditions. Transmission of the bacterium is by aerosol, or by direct contact with infected pigs.

15

Pleuropneumonia can occur in swine of all ages, and there are no known associations with predisposing viral or bacterial infections. *A. pleuropneumoniae* infection may be chronic or acute, with the disease being characterised by increasingly severe pulmonary distress, which progresses rapidly to death, or to a
20 chronic infection resulting in a failure to thrive. A hemorrhagic, necrotic bronchopneumonia with accompanying fibrinous pleuritis is typically observed.

Fifteen different serotypes of *A. pleuropneumoniae* have been identified based on antigenic differences in their capsular polysaccharides, and their production of
25 extracellular toxins. Serotypes 1, 5 and 7 are the most common forms of *A. pleuropneumoniae* infection in the United States, whereas serotypes 1, 2, 5, 7 and 9 predominate in Europe.

Treatment of pigs infected with *A. pleuropneumoniae* usually involves the direct
30 injection of an antibiotic (typically tetracycline). Such a method is however labour intensive, time consuming, and expensive, and can often be of limited use due to the rapid progression of the disease. Evidence from field and experimental studies

- 2 -

has however shown that infection with *A. pleuropneumoniae* can provide a lifetime protection against subsequent reinfection, thereby suggesting that vaccination might be a feasible alternative to antibiotic therapy. The development of an effective vaccine has so far been hampered by the antigenic diversity of the fifteen different serotypes.

In attempts to produce a vaccine composition, killed, whole cell bacteria were found to provide only serotype-specific protection, but it has been shown that natural infection with a highly virulent serotype can stimulate a strong protective cross-immunity against multiple serotypes [Nielsen, Nord Vet Med. 31: 407-13 (1979); Nielsen, Nord Vet Med. 36: 221-234 (1984); Nielsen, Can J Vet Res. 29: 580-582 (1988); Nielsen, ACTA Vet Scand. 15: 80-89 (1994)]. Certain undefined live attenuated mutants have also shown promise for cross-protection of swine [Inzana *et al*, Infect Immun. 61: 1682-6 (1993); Paltineanu *et al*, In International Pig Veterinary Society, 1992, p.214; Utrera *et al*, In International Pig Veterinary Society, 1992, p.213] but because of the uncertainties associated with vaccines comprising bacterial strains having such undefined spontaneous mutations, there exists a need in the art for the rational construction of live attenuated strains which will safely stimulate protective immunity against homologous, and preferably heterologous *Actinobacillus pleuropneumoniae* serotypes. There also exists a need to identify the genes involved in *A. pleuropneumoniae* virulence, to facilitate the development of methods for identifying anti-bacterial agents which target those genes and/or their products.

Published International patent application WO 00/61724 (Pharmacia & Upjohn) describes the use of signature tagged mutagenesis (STM) to identify genes responsible for the virulence of gram-negative bacteria. The development of vaccines containing attenuated bacteria is also discussed. The work is also described in Fuller *et al*, Microbial Pathogenesis [2000] vol. 26; pp.39-51.

30

In the STM technique, a plurality of different bacterial strains, each of which carries a random mutation in its genome, is produced by means of transposon integration.

- 3 -

The inserted transposons carry different DNA signature tags, which allows individual mutants to be differentiated from one other. The tags each comprise a variable central region flanked by invariant "arms", the latter of which allow the variable central portion to be amplified by PCR. Multiple tagged mutant strains are collected
5 in microtiter dishes, and then combined to form an "inoculum pool" for animal infection.

At an appropriate time after infection, bacteria are isolated from the infected animal, and are combined to form a "recovered pool." The tags in the recovered pool and the tags in the inoculum pool are separately amplified, labelled, and used to probe
10 filters arrayed with all the different tags from the mutants in the inoculum. Mutant strains with attenuated virulence are generally those which cannot be recovered from the infected animal, i.e. strains with tags that give hybridization signals when probed with tags from the inoculum pool, but not when probed with tags from the recovered pool. The advantage of STM is that a large number of insertional mutant
15 strains can be simultaneously screened in a single animal for loss of bacterial virulence. STM is more fully described in e.g. WO 96/17951.

After considerable research, the present inventors have provided improved methods and means for identifying genes involved in *A. pleuropneumoniae* virulence. This
20 has led to the identification of a new family of "virulence genes" the members of which each comprise a nucleotide sequence which is selected from any one of those defined by SEQ ID NO: 1-56. As used herein, the term "virulence genes" refers to genes of a bacterium whose correct function is involved in, e.g. required for the establishment and/or maintenance of an infection in a host animal. Virulence genes
25 and their products, which may be polynucleotides (e.g. rRNA) and/or polypeptides, are thus involved in the pathogenesis of the bacterium, but might not be necessary for its growth *in vitro*.

Mutations in virulence genes can result in an "attenuated bacterium", i.e. one whose
30 ability to establish and/or maintain a bacterial infection in a host animal is reduced, as compared to a corresponding wild-type bacterium of the same strain and serotype. Attenuation of the bacterium may be confirmed by means of its

- 4 -

administration to a subject animal, where its inability to cause a sustained infection leading to e.g. chronic infection or death may be observed. The non-establishment of symptoms of porcine pleuropneumonia, e.g. of pulmonary distress, hemorrhagic necrotic bronchopneumonia and/or fibrinous pleuritis, may also be used as an index
5 of bacterial attenuation. Attenuated bacteria are of commercial importance in vaccine compositions.

In one aspect, the present invention thus provides an attenuated *Actinobacillus pleuropneumoniae* bacterium.

10

In a particular embodiment, the present invention provides an attenuated *Actinobacillus pleuropneumoniae* bacterium having a mutation in a gene which comprises a nucleotide sequence selected from the group consisting of SEQ ID NO.:1-56.

15

The mutation may inhibit or prevent the function of the gene, e.g. by reducing the level of its expression (e.g. by reducing transcription and/or translation), and/or by impairing the biological activity of the gene product, e.g. by causing an inactive form of the gene product that is encoded by the mutated gene to be produced. The gene
20 product may be a polynucleotide or polypeptide.

The mutation in the gene may be an insertion, deletion or substitution. It may be located in a region of the gene that encodes a polypeptide, or in a sequence responsible for, or involved in, the control of gene expression, e.g. in a promoter
25 region. Mutations which involve a combination of one or more of insertion, deletion and/or substitution are also contemplated. Attenuated *A. pleuropneumoniae* strains of the present invention likewise include those which have two or more mutations, each of which may be an insertion, a deletion, a substitution, or a combination thereof. Multiple mutations may occur in a single gene, or they may occur in different
30 genes within the same bacterial genome. They may result in an additive or synergistic level of attenuation. Multiple mutations may be prepared by design, or may fortuitously arise as a result of techniques for introducing a single mutation.

Deletion mutants include those in which all or part of the virulence gene is deleted. In one aspect, the mutation results in the deletion of at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% of the virulence gene. A deletion may occur in the appropriate nucleotide sequence set forth in SEQ ID NO.:1-56, or it may occur in an adjacent region of the gene, e.g. in an associated control sequence.

10

Deletion mutants can be constructed using any technique which is well known to those skilled in the art. One strategy employs counter-selectable markers, and has been used to delete genes in many different bacteria. For details of this technique, reference may be made to e.g. Reyrat *et al*, Infection and Immunity [1998] vol. 66; pp.4011-4017, and Oswald *et al*, FEMS Microbiol Lett [1999] vol. 179; pp.153-160.

15

The process employs a double selection strategy, in which a plasmid is constructed which encodes both a selectable and a counter-selectable marker, with flanking DNA sequences being derived from both sides of the desired deletion site in the bacterial genome. The selectable marker is used to select for bacteria in which the plasmid has integrated into the genome in the appropriate location and manner. The counter-selectable marker is then used to select for that small percentage of bacteria which spontaneously eliminate the integrated plasmid. A fraction of those resultant bacteria will contain the desired deletion, with no foreign DNA remaining.

20

25

In another technique for achieving a deletion, the *cre-lox* system is used for site specific recombination of DNA. The system consists of 34 base pair *lox* sequences that are recognised by a bacterial *cre* recombinase. If the *lox* sites are introduced into the genomic DNA in an appropriate orientation, a sequence which is flanked by the *lox* sites can be excised by expression of the *cre* recombinase, one copy of the *lox* site being retained. Using standard recombination techniques, it is possible to delete a sequence of interest in the *A. pleuropneumoniae* genome and to replace

30

- 6 -

it with a selectable marker (e.g. a gene encoding kanamycin resistance) which is flanked by *lox* sites. Transient expression of the *cre* recombinase (e.g. from an electroporated suicide (non-replicating) plasmid containing the *cre* gene under the control of a promoter which functions in *A. pleuropneumoniae*) will then result in efficient elimination of the *lox* flanked marker. This process results in a bacterial mutant containing the desired deletion, and one copy of the *lox* sequence.

In another approach to providing a deletion, a target sequence in the *A. pleuropneumoniae* genome can be deleted (replaced) with a marker gene, e.g. a green fluorescent protein (GFP), β -galactosidase or luciferase. DNA segments flanking a desired deletion are prepared by PCR and cloned into a suicide vector for *A. pleuropneumoniae*. An expression cassette, containing a promoter active in *A. pleuropneumoniae* and operably linked to the appropriate marker gene, is then cloned between the flanking sequences. The plasmid is introduced into wild-type bacteria and mutants which both incorporate and express the marker gene are isolated and examined for a desired recombination event (replacement of the wild-type gene with the marker gene).

As for insertion mutants, these include genes in which a stop codon is inserted into an open reading frame (ORF) upstream (5') of the native, i.e. endogenous stop signal. A truncated, inactive form of the (polypeptide) virulence gene product may thus be expressed by the gene. Insertions which cause a frame-shift are likewise contemplated for the production of inactive products. Mutated virulence genes of *A. pleuropneumoniae* will also include those in which a transposon has been inserted into a protein-coding or regulatory sequence of the gene. Attenuated bacteria produced by the STM technique are insertional mutants in which a virulence gene has been rendered non-functional by insertion of a transposon sequence, e.g. Tn10.

Because insertional mutants, e.g. those generated by STM, will still contain all of the genetic information required for bacterial virulence, there is a risk that they could revert to a pathogenic state, e.g. by spontaneous deletion of the inserted sequence. Accordingly, when preparing a vaccine or other therapeutic composition, based on

- 7 -

an insertional mutant, e.g. one identified by STM, it may be desirable to take the information obtained from that STM-derived strain, i.e. the identification of the disrupted virulence gene, and then recreate a mutant in which some, most, or all of that virulence gene has instead been deleted. This should preclude the possibility
5 that the bacterium will revert to a virulent state, thereby to cause pathology, rather than prophylactic protection of a host animal to which it is administered.

In a related aspect, the present invention provides a composition containing the attenuated *A. pleuropneumoniae* bacterium according to the first aspect of the
10 invention. The composition may be an immunogenic composition, i.e. one which is capable of eliciting an antibody response in a host animal to which it is administered. The composition may be a therapeutic (e.g. prophylactic) composition. It may be a vaccine, preferably one whose administration to an animal confers a degree of protection against subsequent infection with serotypes and strains of *A.*
15 *pleuropneumoniae* different from that/those which is/are present in the vaccine itself (cross-protection). The invention further provides for the use of an attenuated *A. pleuropneumoniae* bacterium of the first aspect of the invention for the manufacture of a medicament (e.g. vaccine) for preventing or alleviating an infection of an animal with *A. pleuropneumoniae* and/or for preventing or alleviating symptoms associated
20 with such infection, e.g. for the prophylactic protection of swine against porcine pleuropneumonia.

In order for an attenuated bacterium to be effective in a vaccine composition, the (one or more) mutation(s) in the virulence gene(s) should be significant enough to
25 prevent the pathogen from evoking severe clinical symptoms, but insignificant enough to allow a limited replication and growth of the bacteria in the host animal, thereby to elicit appropriate defence mechanisms resulting in immunological memory. Mutations in genes which are required for (as distinct from merely involved in) virulence are preferred.

30

Compositions of the invention may contain a plurality of different attenuated *A. pleuropneumoniae* bacteria, e.g. bacteria having different mutations in the same

- 8 -

virulence gene, and/or bacteria having similar, or different, mutations in two or more different genes. While it is possible for an avirulent (attenuated) bacterium of the present invention to be administered alone, it is preferably administered in a solid or liquid composition containing one or more suitable adjuvants, diluents, carriers, vehicles and/or excipients, as discussed elsewhere herein. Compositions according to, and for use in the present invention, may thus comprise one or more of these substances, which should be pharmacologically "acceptable", in the sense of being both compatible with the attenuated bacterium, and not deleterious to the animal to be immunized. Additional substances are preferably both sterile and pyrogen free.

10

Examples of adjuvants which may be used in the present invention include oil-based adjuvants such as Freund's Complete Adjuvant and Freund's Incomplete Adjuvant, mycolate-based adjuvants (e.g. trehalose dimycolate), bacterial lipopolysaccharide (LPS), peptidoglycans (e.g. mureins, mucopeptides, or glycoproteins such as N-Opaca, muramyl dipeptide [MDP], or MDP analogs), proteoglycans (e.g. those extracted from *Klebsiella pneumoniae*), streptococcal preparations (e.g. OK432), BiostimTM (e.g. O1K2), the "Iscoms" of EP 109 942, EP 180 564 and EP 231 039, aluminum hydroxide, saponin, DEAE-dextran, neutral oils (such as miglyol), vegetable oils (such as arachis oil), liposomes, Pluronic polyols, the Ribi adjuvant system (see e.g. GB-A-2 189 141) and interleukins, particularly those that stimulate cell-mediated immunity. An adjuvant consisting of extracts of *Amycolata*, a genus of bacteria of the order Actinomycetales, has also been described (US 4,877,612). Proprietary adjuvant mixtures are commercially available. The adjuvant to be used will depend, at least in part, on the recipient animal. The amount of adjuvant to be administered will also depend on the type and size of the animal. Optimal dosages may be readily determined by routine methods well known to those skilled in the art.

As for any diluent(s), carrier(s), vehicle(s) and/or excipient(s), these may be liquid, semisolid, or solid in nature. Any suitable substance known to those skilled in the art may be used. Exemplary substances include polyoxyethylene sorbitan monolaurate, magnesium stearate, methyl and propylhydroxybenzoate, talc, alginates, starches, lactose, sucrose, dextrose, sorbitol, mannitol, gum acacia, calcium phosphate,

30

- 9 -

mineral oil, cocoa butter, and oil of theobroma.

The compositions of the invention may be packaged in various forms which maybe convenient for, or adapted to, a particular route of delivery. Therapeutic
5 compositions (e.g. vaccines) may be suitable for administration to a subject animal by for example intravenous, intradermal, intramuscular, intramammary, intraperitoneal and/or subcutaneous injection, and/or by oral, sublingual, nasal, anal or vaginal delivery. The treatment may consist of a single dose, or of a plurality of doses over a period of time. Decisions on administration regimes are well within the
10 ambit of those skilled in the art. The composition may be formulated and packaged as appropriate.

In a further aspect, the present invention provides an isolated polynucleotide encoding a gene product which is naturally involved in (e.g. required for) the
15 virulence of *A. pleuropneumoniae*. The sequence of the polynucleotide is thus found in a virulence gene of *A. pleuropneumoniae*. The invention also provides for a polynucleotide encoding a gene product which is not naturally found in *A. pleuropneumoniae*, but whose expression therein is capable of modulating (e.g. of decreasing) the virulence of that bacterium. Such a polynucleotide may be
20 introduced into the bacterium to cause such expression (e.g. by transformation, transfection or electroporation). Expression may result in an attenuated strain of the bacterium, e.g. for use in a vaccine or other immunogenic composition. Polynucleotides which are not naturally found in *A. pleuropneumoniae* but which are capable of modulating the virulence of that bacterium by their direct interaction with
25 *A. pleuropneumoniae* virulence genes or gene products (rather than by indirect action through their own gene products) are also contemplated.

Any gene product of a polynucleotide according to the present invention may be a polynucleotide (e.g. RNA) or a polypeptide. Polypeptide gene products are herein
30 referred to as "virulence polypeptides", and are involved in/capable of modulating the virulence of *A. pleuropneumoniae*, whether or not they are naturally encoded by the wild-type bacterial genome. Polynucleotide gene products which can affect the

- 10 -

virulence of *A. pleuropneumoniae* include e.g. antisense RNA and ribozymes. An effect on bacterial virulence may be demonstrated for any gene product by determining the extent to which a strain of the bacterium *A. pleuropneumoniae* which expresses the product can establish and/or maintain an infection in an animal
5 as compared with *A. pleuropneumoniae* of the same strain and serotype which does not express the product.

According to this aspect, the present invention more particularly provides for an isolated polynucleotide comprising (e.g. consisting of): (a) a nucleotide sequence
10 selected from the group consisting of SEQ ID NO.: 1-56 (such sequences are found within the virulence genes of *A. pleuropneumoniae* as identified elsewhere herein); (b) a nucleotide sequence encoding the polypeptide which is encoded by the nucleotide sequence recited in (a); (c) a nucleotide sequence which hybridizes to the nucleotide sequence of (a) and/or (b), or to its complement, under conditions of
15 moderate to high stringency; or (d) a fragment of any one of the nucleotide sequences of (a)-(c), which fragment retains an immunological property and/or a biological activity of the recited nucleotide sequence of (a)-(c). Polynucleotides of the present invention may be DNA or RNA, as described elsewhere herein.

20 Nucleotide sequences of type (b) can be readily identified once an amino acid sequence is derived from the nucleotide sequence of (a), and account is taken of the genetic code.

As to (c), exemplary conditions of moderate stringency include a final wash in a
25 buffer comprising 2xSSC/0.1% SDS, at 35°C to 45°C. Exemplary conditions of high stringency include a final wash in a buffer comprising 0.2xSSC/0.1 % SDS, at 65°C to 75°C. It is understood in the art that conditions of equivalent stringency can be achieved by means of variation of temperature and buffer or of salt concentration. In this regard, reference may be made to Ausubel *et al*, Protocols in Molecular
30 Biology, John Wiley & Sons (1994), pp.6.0.3 to 6.4.10. Modifications in hybridization conditions can be empirically determined or precisely calculated based on length and percentage of guanosine/cytosine (GC) base pairing. Hybridization conditions

can be calculated as described in Sambrook *et al*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (1989), pp. 9.47 to 9.51.

- 5 For fragments of type (d), knowledge of the nucleotide sequence according to (a), (b) or (c) makes available to the skilled person every possible fragment of that nucleotide sequence. Fragments may be at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 nucleotides in length. They may be capable of hybridising to the nucleotide sequence of (a), (b) or
- 10 (c), or to its complement, under conditions of moderate to high stringency, optionally in the presence of competitive nucleic acid, e.g. in the presence of nucleic acid from a cDNA or mRNA library derived from *A. pleuropneumoniae*. The retained immunological property may be an ability of the fragment to be bound specifically by an antibody which binds specifically to the full length nucleotide sequence.
- 15 Binding affinities of at least 10^7 M^{-1} are contemplated. A retained biological activity may be an ability of the fragment to encode a polypeptide which shares a binding capability with the polypeptide encoded by the full length nucleotide sequence, e.g. an ability to bind to one of the ligands to which it naturally binds *in vivo*, or the same antibody.

20

- As will be readily apparent to the person of skill in the art, the identification of virulence genes of *Actinobacillus pleuropneumoniae* enables the identification of corresponding (i.e. homologous) genes in other related bacteria, e.g. in other members of the *Pasteurellaceae* family. In isolated form, such gene sequences may
- 25 be encompassed within the claimed polynucleotides comprising (or consisting of) a nucleotide sequence according to type (c) above. Southern hybridization using the nucleotide sequences of type (a) (or fragments thereof) as probes, can identify such related sequences in genomic, cDNA or mRNA libraries from other bacteria. Alternatively, the use of PCR, with primers comprising the *A. pleuropneumoniae*
- 30 sequences or fragments thereof, can be equally as effective for identifying virulence genes across species boundaries. As a further alternative (which does not rely on hybridisation but still identifies homologous genes) complementation of an *A.*

- 12 -

pleuropneumoniae mutant strain with a polynucleotide (e.g. DNA or mRNA) library from another species, can be used to identify genes having the same, or a related biological activity. In short, polynucleotides of the invention, which comprise a nucleotide sequence according to type (c), may be found in, or constitute, virulence genes of other bacteria related to *A. pleuropneumoniae*.

Identification of related virulence genes can lead to the production of an attenuated strain of the other organism by mutation in that gene, and may therefore be used in the production of vaccines and other immunological compositions. In yet further aspects, the present invention thus provides: (1) an attenuated bacterium (e.g. of the *Pasteurellaceae* family) containing a mutation in a gene comprising a nucleotide sequence which is capable of hybridising to any one of the nucleotide sequences defined by SEQ ID NO:1-56, under conditions of moderate to high stringency; (2) a composition (e.g. a vaccine) containing such a bacterium; and (3) the use of such a bacterium for the manufacture of a medicament (e.g. a vaccine) for the therapeutic treatment or prophylactic protection of an animal against infection by the corresponding wild-type bacterium (or a different strain or serotype thereof).

As explained elsewhere herein, polynucleotides of the present invention of types (a)-(d) may be e.g. DNA, RNA, or peptide nucleic acids, as described for example in Corey, TIBTECH 15: 224-229 (1997). DNA sequences include those derived (extracted or amplified) from genomic DNA, or from cDNA, as well as wholly or partially chemically synthesized nucleotide sequences. Amplification may be effected by any method well known to those skilled in the art, e.g. by PCR.

25

"Chemically synthesized" as used herein refers to purely chemical, as opposed to enzymatic (e.g. PCR-based) methods for producing polynucleotides. "Wholly" synthesized polynucleotides are those produced entirely by chemical means, and "partially" synthesized polynucleotides include those wherein only portions of the resulting sequence are produced by chemical means.

30

The polynucleotides of the invention, or their gene products, may be ribozymes.

Such polynucleotides may comprise or consist of an (RNA) nucleotide sequence according to type (c) above, i.e. one which is capable of hybridising to any of the nucleotide sequences recited in (a) or (b) under conditions of moderate to high stringency. For a review of ribozyme technology, reference is made to Gibson and Shillitoe, Mol. Biotech. 7: 125137 (1997). A ribozyme can be utilized to inhibit the translation of mRNA (e.g. mRNA transcribed from virulence genes) in a sequence specific manner, e.g. by: (i) the hybridization of a complementary RNA sequence in the ribozyme to the target mRNA; and (ii) cleavage of the hybridized target mRNA through nuclease activity inherent to the ribozyme. The polynucleotides of the invention may therefore be used to inhibit the expression of virulence genes of *A. pleuropneumoniae* or of other related e.g. *Pasteurellaceae* bacteria. Ribozymes can be identified by empirical methods, but they may be specifically designed based on accessible sites on the target mRNA, e.g. on the mRNA transcription product of the nucleotide sequences defined by SEQ ID NO:1-56 (see also Bramlage *et al*, Trends in Biotech 16: 434-438 (1998)).

Delivery of ribozymes to target cells, in order to control mRNA translation, may be accomplished using delivery techniques well known to those skilled in the art. Exogenous delivery methods can include the use of targeting liposomes or direct local injection. Endogenous methods include the use of viral vectors and of non-viral plasmids.

Certain polynucleotides of the present invention may also be used to modulate the transcription of virulence genes in *A. pleuropneumoniae*, e.g. by means of oligonucleotide-directed triplet helix formation. For a review of this technique, reference is made to Lavrovsky *et al*, Biochem. Mol. Med. 62: 11-22 (1997). Triplet helix formation is accomplished using sequence specific oligonucleotides which hybridize to double stranded DNA in the major groove (as defined in the Watson-Crick model). Hybridization of such sequence specific oligonucleotides can thereafter modulate the activity of DNA-binding proteins, including, for example, transcription factors and polymerases. Preferred target sequences for hybridization include transcriptional regulatory regions that modulate the expression of virulence

- 14 -

genes. Oligonucleotides which are capable of triplet helix formation are also useful for site-specific covalent modification of target DNA sequences in virulence genes. Oligonucleotides useful for covalent modification are coupled to DNA damaging agents as described for example in Lavrovsky, *et al*, Biochem. Mol. Med. 62: 11-22
5 (1997).

In yet another aspect, the present invention provides a vector comprising a polynucleotide according to the present invention. The vector may be DNA or RNA in nature. It may contain one or more control sequences operably linked to the
10 polynucleotide, in order to promote its transcription, and optionally enable its translation, in a suitable host cell under appropriate conditions. Vectors may be plasmids, or viral vectors. They may be capable of autonomous replication. Control sequences may be endogenous (i.e. found within the wild-type bacterium from which the polynucleotide of the invention is derived, e.g. *A. pleuropneumoniae*) or they
15 may be exogenous (e.g. a control sequence found in a related bacterium, e.g. in another member of the *Pasteurellaceae* family). Control sequences include *inter alia* promoters and transcription terminators.

Host cells containing (e.g. transformed, transfected, or electroporated with) a
20 polynucleotide or vector of the present invention are further contemplated. Such host cells may be prokaryotic or eukaryotic in nature, either stably or transiently transformed, transfected, or electroporated with a polynucleotide or vector of the present invention, in a manner which permits the transcription of the polynucleotide, and optionally enables translation of the resultant mRNA. Host cells of the invention
25 include bacterial, yeast, fungal, invertebrate, and mammalian cells. Viruses containing a polynucleotide or vector of the present invention are also contemplated.

Host cells of the present invention may be useful in methods for the large scale production of virulence polypeptides (where the polynucleotide of the invention
30 encodes a polypeptide sequence). The cells are grown in a suitable culture medium under favourable conditions, and the desired polypeptides are isolated from the cells, or from the medium in which the cells are grown, by any purification technique

- 15 -

well known to those skilled in the art, e.g. by capture on an affinity column. Such cells may be a valuable source of immunogen for the development of antibodies which specifically bind to the virulence polypeptide. Any suitable host cell may be used for the expression of a polynucleotide according to the present invention.

5

For this and other purposes, polynucleotides of the present invention may be manipulated using standard techniques well within the ambit of those skilled in the art, e.g. the techniques described in Sambrook *et al*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (1989). By way of example, the polynucleotides of the invention may be amplified and cloned by e.g. PCR, e.g. using genomic DNA, cDNA or mRNA as a template. For ease of inserting the cloned sequence into vectors, e.g. expression vectors, PCR primers may be chosen so that the PCR-amplified sequence has a restriction enzyme site at the 5' end which precedes the initiation codon ATG, and
10 a restriction enzyme site at the 3' end after the termination codon TAG, TGA, or TAA. If desirable, the codons in the cloned sequence may be changed, without changing the amino acids, according to the codon preference of an intended host cell, e.g. *E. coli*, as described by Grosjean and Fiers, Guide, 18: 199-209 (1982) and
15 Konigsberg and Godson, Proc. Natl. Acad. Sci. (USA), 80: 687-691 (1983).
20 Optimization of codon usage may lead to an increase in the expression of the gene product when produced in that host.

If a virulence polypeptide is to be produced extracellularly, e.g. in the periplasm of a host bacterium, or in the culture medium surrounding a host cell, then the
25 polynucleotide of the present invention may be cloned without its initiation codon, and placed into an expression vector behind an appropriate signal sequence. A number of signal sequences from both prokaryotes and eukaryotes are known to function in the secretion of recombinant proteins. During the protein secretion process, the signal peptide may be removed by a signal peptidase to yield the
30 mature protein.

To simplify the purification of virulence polypeptides, a purification tag may be added

- 16 -

to the 5' and/or 3' end of the polypeptide encoding sequence. Commonly used purification tags include a stretch of six histidine residues (US Patent Nos. 5,284,933 and 5,310,663), a streptavidin-affinity tag described by Schmidt and Skerra, Protein Engineering, 6: 109-122 (1993), a FLAG peptide (Hopp et al., Biotechnology, 6: 12051210 (1988)), glutathione S-transferase (Smith and Johnson, Gene, 67: 31-40 (1988)), and thioredoxin (LaVallie et al., BioTechnology, 11: 187-193 (1993)). To remove these tags, a proteolytic cleavage recognition site may be inserted at the fusion junction. Commonly used proteases are factor Xa, thrombin, and enterokinase.

10 In a further aspect, the present invention provides a method of producing a virulence polypeptide encoded by a polynucleotide of the invention. The method may comprise the steps of: (i) culturing a host cell according to the present invention under conditions which permit the expression of the polypeptide; and (ii) recovering and optionally isolating the expressed polypeptide from the host cell, or from its
15 surrounding medium. Identification of the polynucleotides of the present invention readily makes available their encoded polypeptides, so such polypeptides can alternatively be chemically synthesised.

Polypeptides encoded by polynucleotides of the present invention (and variants of
20 such polypeptides) are a further aspect of the invention. Such polypeptides are "virulence polypeptides", as discussed elsewhere herein. Compositions containing such polypeptides are further contemplated, and these include vaccines and other immunogenic compositions. Such compositions may contain one or more adjuvants, carriers, diluents, vehicles or excipients, as discussed elsewhere herein.

25 Variants include biologically and/or immunologically active fragments of the polypeptide encoded by a polynucleotide of the invention, e.g. fragments of the polypeptide encoded by the polynucleotide sequence defined in any one of SEQ ID NO.:1-56, fusions of the polypeptides or fragments thereof with e.g. heterologous
30 polypeptides (thereby to produce chimeras), and analogs of the polypeptides, e.g. polypeptides in which one or more amino acids has been deleted, replaced or added: (i) without loss of one or more of the biological activities and/or

- 17 -

immunological characteristics specific for the polypeptide; or (ii) with specific disablement of a particular biological activity of the polypeptide. Replacement may occur using conservative amino acids.

- 5 Virulence polypeptides having an additional methionine residue at position -1 are contemplated, as are virulence polypeptides having additional methionine and lysine residues at positions -2 and -1. Variants of these types are particularly useful for recombinant protein production in bacterial cell types. The invention also embraces variants having additional amino acid residues which result from the use of specific
- 10 expression systems. For example, use of commercially available vectors that express a desired polypeptide as a fusion protein with glutathione-S-transferase (GST) provide the desired polypeptide having an additional glycine residue at position -1 after cleavage of the GST component from the desired polypeptide. Variants of polypeptides of the present invention also include those in which a leader
- 15 or signal sequence has been removed, e.g. a mature form.

Variant polypeptides include those which have at least about 99%, at least about 95%, at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 70%, at least about 65%, at least about 60%, at least about

20 55%, and at least about 50% sequence identity and/or homology with a virulence polypeptide encoded by a nucleotide sequence as defined in any one of SEQ ID NO.:1-56. Percentage "identity" of an amino acid sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the virulence polypeptide, after aligning both sequences and

25 introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Percent "homology" of an amino acid sequence with respect to a virulence polypeptide encoded by any one of SEQ ID NO:1-56 refers to the percentage of amino acid residues in the candidate sequence that are identical with the residues

30 in the virulence polypeptide after aligning the two sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and also considering any conservative substitutions as part of the sequence identity.

- 18 -

By conservative substitution is meant exchange of one amino acid for an amino acid of the same type, the types being as follows:

Aliphatic Non-polar :	G A P I L V
5 Polar-uncharged sulphur :	C M
Polar-uncharged hydroxyl:	S T
Polar-charged acidic:	D E N Q
Polar-charged basic:	K R H
Aromatic:	F W Y

10

In a still further aspect, the present invention extends to antibodies which specifically recognize the polynucleotides or polypeptides of the present invention. Antibodies may be monoclonal or polyclonal antibodies. They include chimeric antibodies, e.g. humanized antibodies, e.g. complementary determining region (CDR)-grafted
15 antibodies, as well as fragments of antibodies (which may be chimeric) e.g. Fab, F(ab')₂, Fd and single chain antibodies. They also include compounds having CDR sequences which specifically recognize a polynucleotide or polypeptide of the present invention. The invention also provides anti-idiotypic antibodies which specifically bind to antibodies of the present invention.

20

The term "specific for" indicates that the variable regions of the antibodies of the invention exclusively recognize a target polypeptide or polynucleotide (i.e. they are able to distinguish a single polypeptide or polynucleotide from related polypeptides or polynucleotides). Binding affinities of at least about 10^7 M^{-1} , at least about 10^8 M^{-1} , or at least about 10^9 M^{-1} are contemplated. That is not to say that the antibodies
25 will not also interact with other proteins (for example, *S. aureus* protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and in particular, in the constant region of the molecule. Screening assays to determine binding specificity of an antibody of the
30 invention are well known and routinely practised by those skilled in the art. For a comprehensive discussion of such assays, reference may be made to Harlow et al. (Eds), Antibodies. A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring

Harbor, NY (1988), Chapter 6.

According to a still further aspect of the present invention, materials and methods are provided for identifying an anti-bacterial agent which is capable of modulating the function of an *A. pleuropneumoniae* virulence gene identified by the present invention, or of a homologous gene in a related species. Agents which are capable of modulating the function of such virulence genes are likewise contemplated *per se*. More particularly, methods of the present invention include screening potential agents for their ability to interfere with the expression and/or biological activity in a host bacterium of the gene products encoded by the nucleotide sequences set forth in any one of SEQ ID NO:1-56. Agents that interfere with the expression of virulence gene products include (but are not limited to) anti-sense polynucleotides and ribozymes containing nucleotide sequences which are homologous to any one of the nucleotide sequences of SEQ ID NO:1-56 (such that they bind to its complement). The invention further embraces methods of modulating the transcription of such virulence genes through the use of oligonucleotide-directed triplet helix formation.

Compositions containing an anti-bacterial agent identified in accordance with the present invention are a still further aspect of the present invention, in addition to a method of treating an animal suffering from a *Pasteurellaceae* (e.g. an *A. pleuropneumoniae*) infection by administration of such an anti-bacterial agent or composition. The invention also embraces the use of such an agent or composition for the manufacture of a medicament for the treatment of a *Pasteurellaceae* infection, e.g. an *A. pleuropneumoniae* infection and/or porcine pleuropneumonia.

Agents that interfere with the function of virulence genes encompass: (i) non-functional variants of the virulence gene products which may be capable of out-competing the wild-type product for its physiological binding sites; and (ii) binding partners of the virulence gene products, which sequester and optionally destroy said products. Agents also include allosteric enzyme inhibitors, in the case where the virulence gene product is an enzyme.

- 20 -

Inhibitory agents may be identified by means of high throughput screening assays using the polynucleotides of the present invention or their encoded products (which may be RNA polynucleotides or polypeptides). Where the screen employs polypeptide gene products having enzymatic activity, assays are established which are based on that activity, and potential agents screened for an ability to modulate (e.g. inhibit) the activity. For virulence gene products which exert their function by interacting with a polypeptide or nucleic acid, binding assays are established to measure such interaction, and potential agents are screened for an ability to modulate, e.g. to inhibit the interaction.

10

In one example of a binding assay, the virulence gene product is immobilized on a solid support, and an interaction with a (physiological) binding partner is assessed in the presence and absence of a putative inhibitor compound. In another example, interaction between the virulence gene product and its binding partner is assessed in a solution assay, both in the presence and absence of a putative inhibitor compound. In both assays, an inhibitor is identified as a compound that decreases binding between the virulence gene product and its binding partner. Assays for use when the virulence gene product and its binding partner are both polypeptides include variations of the di-hybrid assay, wherein an inhibitor of protein/protein interaction is identified by detection of a positive signal in a transformed or transfected host cell, as described for example in published International patent application WO 95/20652.

Candidate inhibitors contemplated for use in the methods of the present invention include compounds selected from libraries of potential inhibitors. A number of different libraries can be used as a source of small molecule modulators, including: (1) chemical libraries; (2) natural product libraries; and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules.

30 Chemical libraries consist of structural analogs of known compounds. Natural product libraries are collections of microorganisms, animals, plants, or marine organisms which are used to create mixtures for screening by: (i) fermentation and

- 21 -

- extraction of broths from soil, plant or marine microorganisms; or (ii) extraction of plants or marine organisms. Natural product libraries are further discussed in e.g. Science 282: 63-68 (1998). As for combinatorial libraries, these are composed of large numbers of peptides, oligonucleotides, or organic compounds as a mixture.
- 5 They are relatively easy to prepare by traditional automated synthesis methods, PCR, cloning, or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries. For a review of combinatorial chemistry libraries, reference may be made to Myers, Curr. Opin. Biotechnol. 8: 701-707 (1997).
- 10 Still other candidate inhibitors, which are contemplated for use in the methods of the invention, may be specifically designed. These include soluble forms of the binding partners of virulence polypeptides. The term "binding partners" as used herein encompasses antibodies (although in certain embodiments these are excluded) including fragments and derivatives thereof, and modified compounds comprising
- 15 antibody domains that specifically bind to the target gene product.

When a polypeptide binding partner for a virulence gene product is not known, assays that identify physiological, or non-physiological and hence sequestering binding partners may be employed, e.g. assays using affinity columns on which the

20 virulence gene product is immobilised. Alternatively, binding interactions between polypeptides may be identified using the yeast two-hybrid system as described in Fields and Song, Nature, 340: 245-246 (1989), and Fields and Sternglanz, Trends in Genetics, 10: 286-292 (1994). Other assays which may be used to search for agents that bind to a polypeptide virulence gene product include that described in

25 US Patent No. 5,585,277, which relies on the principle that proteins generally exist as a mixture of folded and unfolded states, and continually alternate between the two states. When a test ligand binds to the folded form of a target virulence polypeptide, the target protein molecule bound by the ligand remains in its folded state. Thus, the folded target protein is present to a greater extent in the presence

30 of a test ligand which binds the target protein, than in the absence of a ligand. Binding of the ligand to the target protein can be determined by any method which distinguishes between the folded and unfolded states of the target protein. The

- 22 -

function of the target protein need not be known in order for this assay to be performed. Virtually any agent can be assessed by this method as a test ligand, including, but not limited to metals, polypeptides, including proteins, lipids, polysaccharides, polynucleotides and small organic molecules.

5

Another method for identifying ligands of a virulence gene polypeptide is that described in Wieboldt *et al*, Anal. Chem., 69: 1683-1691 (1997). That technique screens combinatorial libraries of 20-30 agents at a time in solution phase for binding to the target virulence polypeptide. Agents that bind to the target are
10 separated from other smaller library components by centrifugal ultra-filtration. The specifically selected molecules that are retained on the filter are subsequently liberated from the target protein and analysed, e.g. by HPLC and pneumatically assisted electrospray (ion spray) ionization MS. This procedure selects library components with the greatest affinity for the target protein, and is particularly useful
15 for libraries of small molecules.

Binding agents identified by the initial screens maybe evaluated for their effect on virulence *in vivo*. Agents that interfere with bacterial virulence can prevent the establishment of an infection, or reverse the outcome of an infection once it is
20 established. Binding agents may be included in compositions containing pharmaceutically acceptable adjuvants, excipients, diluents, carriers or vehicles, as described elsewhere herein.

Numerous additional aspects and advantages of the invention will now become
25 apparent to those skilled in the art upon consideration of the following detailed description of the invention which describes presently prepared embodiments thereof.

30 EXPERIMENT 1

A. Materials and Methods

1. Bacterial strains and growth conditions

A spontaneously nalidixic acid-resistant derivative of the virulent *Actinobacillus pleuropneumoniae* serotype 1 strain 4074 was selected using conventional methods and designated 4074 Nal^R. The virulence of this strain was verified by passage in pigs. *A. pleuropneumoniae* strains were propagated at 37°C with 5% CO₂ on brain-heart infusion (BHI) plates supplemented with 10% Levinthal's base (BHI_L), or at 37°C in Colombia broth with 5µg/ml β-nicotinamide adenine dinucleotide (NAD) and 11mM CaCl₂.

The *E. coli* strains used in this study were: S17 λ pir [*recA thi pro hsdR*^{M+} *RP4::2-Tc::Mu::Km* Tn7 lysogenized with λ pir phage] as described in Miller and Mekalanos (1988) J. Bacteriol. 170, pp.2575-2583; CC118 λ pir [*Δ(are-leu) araD Δ lacX74 galE galK phoA20 thi-1 rpsE rpoB argE recA1* lysogenized with λ pir phage] as described in de Lorenzo *et al*, (1990) J. Bacteriol. 172, pp. 6657-6667; and XL1-Blue (*recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F' proAB lac^R ZΔM15 Tn10 (Tet^r)*). *E. coli* strains were maintained in Luria-Bertani (LB) medium with appropriate antibiotics used at the following concentrations: ampicillin 100µg/ml; kanamycin 100µg/ml; nalidixic acid 20µg/ml; tetracycline 10µg/ml.

2. DNA manipulations, amplification, labelling, and hybridisation of tags

Chromosomal DNA was isolated from *A. pleuropneumoniae* using a QIAamp mini DNA kit (Qiagen) according to the manufacturer's instructions. Plasmid DNA was isolated from *E. coli* using a Qiagen plasmid midi kit, again according to the manufacturer's instructions. DNA manipulation was performed according to standard techniques as described in Sambrook *et al*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (1989). Probes for southern blots were labelled with [digoxigenin (DIG)-11]-dUTP using a PCR DIG Probe Synthesis Kit (Roche) as described by the manufacturer. Amplification and labelling of DNA signature-tags was performed as described in

- 24 -

Hensel *et al* (1995) Science 269 pp.400-403. Tags were initially amplified from genomic DNA by means of PCR using the following primers:

P6 (5'-CGACTACAACCTCAAGCT-3')

5

P7 (5'-CGACCATTCTAACCAAGC-3')

The amplified tags were purified on a 2% Nusieve GTG agarose gel and radiolabelled with [³²P]-dCTP in a second PCR, again using P6 and P7. The cycling conditions for both PCRs were as follows: denaturation and enzyme activation
10 12min at 95°C, followed by 20 cycles of: 95°C for 30s, 50°C for 45s and 72°C for 10s. Reactions were performed using 1 unit of AmpliTaq Gold (Perkin-Elmer) polymerase in a Perkin-Elmer 2400 thermocycler. Prior to use, the invariant flanking DNA was separated from the variable signature-tag by digestion with *HindIII* for 18h at 37°C.

15

For colony blots, *E. coli* S17 λ pir strains harbouring each of the pLOF/TAG 1-48 plasmids were grown to mid-exponential phase and 100 µl of each culture was transferred to the wells of a microtitre dish. Bacteria were transferred from the microtitre dish to a nylon membrane (Hybond N) using a replica plater (Sigma) and
20 the inoculated membrane placed on the surface of a dried LB agar plate containing ampicillin (100µg/ml). After overnight growth at 37°C, the membranes were treated with 1.5 M NaCl, 0.5 M NaOH for 10min. DNA was fixed to the membrane by microwaving at maximum power for 30s and bacterial debris removed by washing in 2XSSC. Pre-hybridisation and hybridisation were performed at 65°C in Rapid-hyb
25 buffer (Amersham) for 1h and overnight, respectively. Blots were washed according to standard procedures. To identify potentially attenuated mutants, hybridisation signals on a blot probed with labelled tags prepared from the input pool (inoculum) were compared to identical blots hybridised with labelled tags prepared from the corresponding output pools from at least two different animals.

30

3. Construction of DNA signature-tags and pLOF/TAG 1-48

- 25 -

Double-stranded DNA signature tags were obtained by PCR amplification of the variable oligonucleotide pool RT1 (Hensel *et al*, 1995 Science 269 pp.400-403) using the following primers:

5 P3SAL (5'-CGCCATGTCGACCATTCTAACCAAGCTT-3')
 P5SAL (5'-CGCCTAGTCGACTACAACCTCAAGCTT-3')

each of which contains recognition sites for the restriction endonuclease *Sall* at its 5' terminus. To facilitate the cloning of the signature-tags in plasmid pLOF/Km, the
10 plasmid was modified to incorporate a unique *Sall* site. This was done by annealing the following complementary oligonucleotides:

 SALTOP (5'-GTCGACCCT-3') and
 SALBTM (5'-GTCGACAGG-3').

15 to give a double-stranded linker containing a *Sall* site flanked by *SfiI*-compatible ends. Plasmid pLOF/Km was digested with *SfiI*, treated with calf intestinal alkaline phosphatase (CIAP), and ligated to the phosphorylated double-stranded linker to give plasmid pLOF/Sal. The PCR-amplified double-stranded DNA signature-tags
20 were digested with *Sall*, gel purified, and cloned into the *Sall*- digested, CIAP-treated, pLOF/Sal to generate a library of uniquely tagged pLOF/TAG plasmids.

Individual transformants in *E. coli* strain CC118 λ pir were screened by colony blot hybridisation with their corresponding [³²P]-dCTP-labelled tags to identify 100 tags
25 that amplified and labelled efficiently. These tags were then tested for an absence of cross-hybridisation and 48 plasmids (pLOF/TAG1-48) were selected for further use.

4. Construction of the signature-tagged mutant bank

30

The 48 signature-tagged mini-Tn10 transposons carried on plasmids pLOF/TAG 1-48 were separately introduced into *A. pleuropneumoniae* by conjugation. *A.*

- 26 -

pleuropneumoniae strain 4074 NaI^R and *E. coli* S17 λ pir harbouring each of the pLOF/TAG 1-48 plasmids were grown overnight at 37°C to the stationary phase of growth. Bacteria were harvested by centrifugation for 15 minutes at 3,000 rpm and washed twice with 10mM MgSO_4 . Approximately equal numbers of *A.*
5 *pleuropneumoniae* recipient and *E. coli* donor cells were mixed, concentrated, and spread onto 0.22 μm filters. Filters were placed onto BHI_L plates containing 1mM IPTG and incubated at 37°C with 5% CO_2 for 5 hours. Thereafter, the bacteria were removed into 5ml sterile PBS and aliquots plated onto BHI_L plates supplemented with nalidixic acid (20 $\mu\text{g}/\text{ml}$) and kanamycin (100 $\mu\text{g}/\text{ml}$). Four separate matings were
10 performed for each of the 48 signature-tagged mini-Tn10 transposons. Transconjugant mutants were screened for susceptibility to ampicillin, thereby to eliminate strains carrying co-integrants of the suicide vector, inserted into the chromosome. In total 2064 transposon mutants from 48 individual matings were isolated and arranged into 43 pools of 48 mutants. Mutants were stored in 1.5ml
15 cryotubes with 15% glycerol at -80°C.

5. Infection studies

Individual strains in each pool of 48 *A. pleuropneumoniae* signature-tagged mutants
20 were grown separately until the mid-exponential phase of growth. At an OD_{600} of approximately 0.3, the individual mutant strains were combined and the pooled culture was diluted in HEPES to approximately 2×10^6 cfu/ml. Large White Cross piglets, of 6-10 weeks of age and determined to be *A. pleuropneumoniae* free by bacteriological and serological analyses, were inoculated intra-tracheally with 3ml
25 of the diluted culture. The number of cfu in the inoculum was verified by viable counts after plating serial dilutions of the inoculum on selective BHI_L. Each mutant pool was used to infect at least two animals.

At approximately 24h post-infection, surviving animals were euthanised and the
30 lungs were removed. Surviving bacteria were recovered from infected lungs by either: (i) extensive lavage with Hanks buffered saline solution (HBSS); or (ii) homogenising the lungs in 500ml HBSS. Aliquots of the bacterial suspension were

- 27 -

plated on selective media, and following growth overnight at 7°C with 5% CO₂, approximately 10,000 colonies were pooled (the "output pool") and total chromosomal DNA was prepared.

5 6. *Competitive indices*

To determine the *in vivo* competitive index (CI) of individual STM mutants, mutant and wild-type bacteria were grown in Colombia broth with 5µg/ml NAD and 11 mM CaCl₂ to an OD₆₀₀ of 0.3. The cultures were then combined to give equal numbers
10 of mutant and wild-type organisms, diluted to 2x10⁶ cfu/ml, and inoculated intra-tracheally into at least two animals. The ratio of mutant to wild-type bacteria in the inoculum was verified by viable counts after plating serial dilutions of the inoculum in parallel on BHI_L + 20µg/ml nalidixic acid (mutant and wild-type), and BHI_L + 20µg/ml nalidixic acid + 100µg/ml kanamycin (mutant only). Approximately 24h post-
15 infection, surviving animals were euthanised and the lungs were removed. The lungs were homogenised in 500ml HBSS and aliquots were plated on selective media (see above) to recover surviving bacteria. The *in vivo* CI was calculated as the output ratio of mutant to wild-type organisms divided by the input ratio of mutant to wild-type organisms. To determine *in vitro* CIs, mutant and wild-type organisms were
20 grown to mid-exponential phase, mixed in equal numbers, and the combined culture incubated, with agitation, at 37°C for a further 3h. Samples were taken at regular intervals, diluted, and plated on selective BHI_L as before, and the *in vitro* CI was calculated as described above.

25 7. *Virulence gene identification and DNA sequencing*

To identify the *in vivo* attenuating lesions, DNA flanking the site of transposon insertion was cloned or amplified by inverse PCR. For cloning, chromosomal DNA was digested with a panel of restriction enzymes, separated by agarose gel
30 electrophoresis, transferred to a nylon membrane, and probed in a Southern blot with a DIG-labelled probe specific for the Tn10 kanamycin gene. Suitably sized fragments hybridising to the probe were excised from a gel, purified and cloned into

- 28 -

appropriately digested pBR322. Transformants in *E. coli* strain XL1-Blue were selected on LB agar containing 100µg/ml kanamycin.

To facilitate sequencing with the Tn10 specific oligonucleotide primer:

5

BS401 (5'-GACAAGATGTGTATCCACC-3')

the cloned insert was further sub-cloned into plasmid pBCKS (Stratagene). Inverse PCR amplification of DNA flanking the site of transposon insertion was performed as described in Fuller, (2000) Microb. Pathog. 29, pp.25-38: chromosomal DNA was digested with SspI (which cuts once in the transposon), diluted to 150 ng/ml, and self-ligated for 15min using the Rapid DNA Ligation Kit (Roche). The ligated DNA was then amplified using the primer pairs BS401 + TEF48, and BS401 + TEF62 (Fuller, 2000 Microb. Pathog. 29, pp.25-38). Reaction conditions for inverse PCR were as previously described (Fuller, 2000 Microb. Pathog. 29, pp.25-38). The resultant amplicons were purified following agarose gel electrophoresis using a QIAQUICK gel extraction kit (Qiagen). DNA sequencing reactions were performed using the BigDye terminator cycle sequencing kit (Perkin-Elmer). Sequences from each of the attenuated mutants were used to query the non-redundant public DNA and protein databases using the BLAST set of similarity search programs (Altschul *et al* 1990 J. Mol Biol. 15, pp.403-410).

B. Results and Discussion

25 1. *Generation of signature-tagged mutants of A. pleuropneumoniae.*

The plasmid pLOF/Km, which is functional in *A. pleuropneumoniae*, was modified to accept signature-tags by the insertion of a unique *SalI* site in the mini-Tn10 element. PCR amplified random signature-tags were cloned into the *SalI* site, and a bank of approximately 30,000 tagged plasmids in *E. coli* CC118 λ pir was obtained. A subset of these transformants was screened by colony blot with their corresponding radiolabelled tags, and signature-tagged plasmids with strong

- 29 -

hybridisation signals were selected. Plasmids with cross-hybridising tags were eliminated, and a pool of 48 unique signature-tagged plasmids was assembled. These plasmids (pLOF/TAG 1-48) were transformed into *E. coli* S17 λ pir, and independently transferred to *A. pleuropneumoniae* strain 4074 NaI^R by conjugation.

5

Following the elimination of ampicillin-resistant plasmid cointegrants (0.5-1%), 2064 transposon mutants from 48 individual matings were isolated, and then arranged into 43 pools of 48 mutants. Southern blot analysis of ten randomly chosen exconjugants with a mini-Tn10-specific probe confirmed single, random insertion of the tagged transposon (data not shown). However, subsequent sequence analysis of attenuated clones revealed that mini-Tn10 insertion in *A. pleuropneumoniae* was not entirely random.

10

2. Signature-tagged screen of *A. pleuropneumoniae* mutants in pigs

15

Signature-tagged *A. pleuropneumoniae* mutants were screened using a porcine intra-tracheal infection model to identify genes involved in virulence. Bacteria were instilled directly into the trachea as previous studies have shown that aerosol particles produced by sneezing are small enough to penetrate into the lower respiratory tract, obviating the need for colonisation of the upper respiratory tract (Kaltreider HB. in Immunologic and infectious diseases in the lung. (1976) pp. 73-97, Kirkpatrick & Reynolds (Eds) Marcel Dekker, New York).

20

A range of experimental factors including the infecting dose, and the method of recovery were investigated before we could reproducibly recover the majority of individual mutants following *in vivo* selection in the porcine host. Using challenge doses of 10^3 , 10^4 , or 10^5 cfu, for example, there was a poor correlation between the infecting dose and the appearance of clinical or morphological signs of disease. Moreover, when different pigs were infected with the same pool, the hybridisation patterns of the post-passage pool suggested that different clones were missing after passage of a given pool through different animals (data not shown). This inconsistency was overcome by increasing the challenge dose to 10^6 - 10^7 cfu/pig.

25

30

- 30 -

In an earlier STM study of *A. pleuropneumoniae* infection in pigs [Fuller, 2000 Microb. Pathog. 29, pp.39-51], bacteria were recovered by lung lavage following
5 experimental infection. However, this method was found to be unreliable, yielding essentially random recovery of individual signature tags. In contrast, we observed consistent recovery of viable bacteria following homogenisation of the entire lung in HBSS. Optimisation of these two crucial parameters resulted in the recovery of the majority of individual clones (>90%, 20-48h post infection), with excellent
10 reproducibility between animals (see Figure 1; compare A and B).

In total, 2064 transposon mutants (43 pools of 48 mutants) were screened for attenuation *in vivo*, each pool being inoculated into at least two different animals. Surviving bacteria were recovered by homogenisation of lungs in sterile HBSS. This
15 initial screen identified 550 mutants present in the input pool but missing or significantly reduced in the output pools. These potentially attenuated mutants were reassembled into new pools and each new pool was used to infect a further two animals. Following this second screen, 105/410 mutants were found to be consistently absent from the output pools, and these were retained for further
20 analysis.

3. *Identification and analysis of A. pleuropneumoniae virulence genes.*

The nucleotide sequence of the DNA flanking the site of transposon insertion was
25 obtained for each of the 105 attenuated mutants as described, and used to search the GenBank databases for homologous genes. The results of this analysis are shown in Table 1, with the genes assigned to one of five functional categories: cell surface, transport, metabolism, stress responses, and regulation. Insertions in genes encoding proteins with no significant homology to proteins in the databases, or
30 homologous to proteins or predicted proteins of unknown function, are categorised as "unknown". The 105 attenuated mutants contained transposon insertions in 53 individual genes and a number of hotspots for Tn10 insertion were identified. In

- 31 -

particular, seven identical insertions were independently isolated in the putative *rfbP* gene (*Tn* insertion at codon 444), 3 of 4 insertions in the *A. pleuropneumoniae fur* gene were located at codon 128. Interestingly, the DNA sequences flanking the 3 hotspots which were identified in this study are neither similar to each other, nor to
5 the consensus sequence for *Tn10* insertion into *A. pleuropneumoniae* that has been previously been identified (Fuller et al (2000) Microb. Pathog. 29, pp.25-38).

(i) Cell surface

10 Mutations in capsule and lipopolysaccharide (LPS) genes are known to attenuate *A. pleuropneumoniae* (Rioux et al., Can. J Microbiol. 45: pgs1017-1026, 1999) (Rioux et al., Microb Pathog 28: pgs 279-289, 2000; Ward et al., Infect Immun 66: pgs 3326-3336, 1998). Mutant 9C2 contains a transposon insertion in the *cpxC* gene that encodes a protein involved in capsule export in *A. pleuropneumoniae*
15 (Ward and Inzana, 1997). This mutant was used as a control (known attenuated) strain the *in vivo* CI experiments. Five genes involved in the synthesis of O-antigen of *A. pleuropneumoniae* serotype 1 were identified in this STM screen. Mutants with inserts in genes 9 (mutant 10B11), 12 (mutant 25B7), 15 (mutant 15A9), 17 (mutant 12D5), and 18 (mutant 21B8) of the O-antigen operon (Labrie et al., 2002, J.
20 Endotox Res. 8: 27-38) were all attenuated. Another mutant, 9B7, has the transposon insertion 20 bases upstream of the *A. pleuropneumoniae galU* gene that encodes a protein involved in synthesis of the LPS core. Mutation of *galU* was previously shown to attenuate *A. pleuropneumoniae* (Rioux et al., 1999). Finally, mutant 26A9 contains an insertion in a gene homologous to *lcbB*, a putative
25 bifunctional polymerase implicated in capsule or LPS biosynthesis in *N. meningitidis* serogroup L.

Strain 4D4 contains a transposon insertion in a gene encoding a putative lipoprotein. Strain 4D4 shows greatest homology to an unknown protein from *P. multocida*, but
30 it is similar to lipoproteins and putative lipoproteins of *H. influenzae* and *H. somnus* [Theisen (1993) Infect Immun 61: 1793-1798]. *H. somnus* LppB binds Congo red dye (a structural analogue of heme) and has been suggested to be a virulence

factor, but this has not been formally proven [Theisen (1993) Infect Immun 61: 1793-1798]. Finally, strain 17A4 contains an insertion in an ORF with homology to the P2 porin protein of *H. influenzae* [Duim et al (1993) Microb. Pathog. 14, pp. 451-462]. The P2 protein constitutes approximately one half of the total outer membrane
5 protein of *H. influenzae* and represents an important target of the immune response to non-typeable *H. influenzae* infection. [Yi et al (1997) Infect. Immun. 65, 150-155].

(ii) Metabolism

10 Strain 10B12 contains a transposon insertion in an ADP-ribose pyrophosphatase (*adpP*) gene homologue. Regulation of cellular levels of ADP-ribose (ADP-ribose is derived from NAD) is important in preventing non-enzymatic ADP-ribosylation of proteins. The *E. coli*, ADP-ribose pyrophosphatase catalyses the hydrolysis of ADP-ribose to ribose-5-P and AMP, compounds that can be recycled as part of nucleotide
15 metabolism [Gabelli et al (2001) Nat Struct. Biol. 8, pp. 467-472].

Strain 10A11 carries an insertion in an argininosuccinate synthase, *argG*, gene homologue. Argininosuccinate synthase catalyses the conversion of citrulline and aspartate into argininosuccinate, linking the urea cycle and the citric acid cycle via
20 the so-called aspartate-argininosuccinate shunt. The aspartate-argininosuccinate shunt provides a metabolic link between the pathways by which amino groups and the carbon skeletons of amino acids are processed. (Glansdorff (1996) Biosynthesis of arginine and polyamines. In *Escherichia coli and Salmonella* (Vol. 1) (Neidhardt, F.C. et al., eds), pp. 408-433, ASM Press).

25

In strain 33C7, the attenuating lesion was found to occur in a gene homologous to *H. influenzae atpA*, encoding the F₁ alpha subunit of F₁F₀ ATP synthase. ATP synthase is responsible for utilising the proton electrochemical gradient across the cytoplasmic membrane for ATP synthesis in cells growing aerobically or
30 anaerobically. All eight subunits of the bacterial enzyme are encoded by the *atp* operon. In *P. multocida* the *atpA* gene is flanked by *atpH* and *atpG*, and while the gene order in *A. pleuropneumoniae* is unknown, both *atpH* and *atpG* have been

implicated previously in the pathogenesis of *A. pleuropneumoniae* infection [Fuller (2000) Microb. Pathog. 29, pp.39-51].

In strain 0A7, the transposon has inactivated the *pntB* gene, encoding the beta
5 subunit of NAD(P) transhydrogenase. Transhydrogenase is an integral membrane protein composed of two subunits, α and β , organised as an $\alpha_2\beta_2$ tetramer. Transhydrogenase couples the redox reaction between NAD(H) and NADP(H) to the translocation of protons across the inner membrane (Penfound & Foster (1996) Biosynthesis and recycling of NAD. In *Escherichia coli and Salmonella* (Vol. 1)
10 (Neidhardt, F.C. et al., eds), pp. 408-433, ASM Press). It plays a key role in energy metabolism, biosynthesis and detoxification.

In strain 19D5, the transposon has inserted in the *A. pleuropneumoniae mrp* gene. The partial *A. pleuropneumoniae mrp* gene sequences available are highly
15 homologous to *mrp* genes from *H. influenzae* and *E. coli*. In *H. influenzae*, the *mrp* gene has been implicated in the biosynthesis of the Gala(1-4) β Gal component of LPS, while in *E. coli* mutations in *mrp* affect the synthesis of thiamine [High et al (1996) FEMS Microbiol. Lett. 145, pp.325-331; Petersen (1996) J. Bacteriol. 178, pp. 5676-5682]. In *A. pleuropneumoniae*, the *mrp* gene is located approximately 1kb
20 upstream from the *apxIVA* gene, encoding the *in vivo*-induced RTX toxin, ApxIV [Schaller (1999) Microbiology 145: 2105-2116].

Strain 29B11 contains a transposon insertion in a *napB* gene homologue, encoding the smaller, dihaem cytochrome c, subunit of heterodimeric periplasmic nitrate
25 reductase (NAP). In *H. influenzae* (and *Pseudomonas sp*) NAP is the sole nitrate reductase and may function to support anaerobic growth in the presence of nitrate [Brige (2001) Biochem. J. 356, pp. 851-858; Fleischmann (1995) Science 269, pp. 496-512; Bedzyk (1999) J Bacteriol 181: 2802-2806]. In *E. coli* the situation is more complex with two membrane bound respiratory nitrate reductases in addition to NAP
30 [Moreno-Vivian (1999) J Bacteriol 181: 6573-6584]. There is evidence to suggest that NAP is a dissimilatory enzyme used for redox balancing. In addition, NAP has been suggested to play a role in adaptation to anaerobic metabolism after transition

- 34 -

from aerobic conditions, the utilisation of alternate reductants, or even as a self-defense mechanism forming high nitrite levels to inhibit the growth of competing bacteria [Moreno-Vivian (1999) J Bacteriol 181: 6573-6584]. Consistent with a role in anaerobic adaptation, transcription of the *Salmonella typhimurium napB* gene is induced, in an Fnr-dependent manner, in cells exposed to anaerobic conditions [Wei and Miller (1999) J. Bacteriol. 181, pp. 6092-6097].

Strain 17B8, contains an insertion in a gene homologous to *H. influenzae ccmH*, required for the assembly of C-type cytochromes, including NAP, in enteric bacteria [Thony-Meyer (1995) J. Bacteriol. 177, pp. 4321-4326; Kranz (1998) Mol Microbiol 29, pp. 383-396]. CcmH is encoded by the final gene of the *ccm* operon and with CcmF and CcmG is believed to catalyse the reduction of disulphide bonds in the cytochrome *c* apoprotein and to facilitate haem attachment [Kranz (1998) Mol Microbiol 29, pp. 383-396]. While in *E. coli* the *nap* and *ccm* operons are contiguous and may be cotranscribed [Grove (1996) Mol Microbiol 19, pp. 467-481] they are located at separate loci in both *H. influenzae* and *P. multocida* [Fleischmann (1995) Science 269, pp. 496-512; May (2001) Proc Natl Acad Sci USA 98, pp. 3460-3465].

Strain 4B9 contains a transposon insertion in a *moaA* gene homologue. In *E. coli* the *moaA-E* genes are required for the synthesis of molybdopterin from GTP [Rivers (1993) Mol Microbiol 8: 1071-1081]. Molybdopterin (molybdopterin guanine dinucleotide) is the principal cofactor found in prokaryotic molybdoproteins including periplasmic nitrate reductase. Expression of the *moa* genes is induced by anaerobiosis [Anderson (2000) J. Bacteriol. 182, pp. 7035-7043] and *Salmonella typhi moaA* mutants are impaired in their ability to replicate within epithelial cells [Contreras (1997) Microbiology 143, pp. 2665-2672].

Mutant 29B12 contains an insertion in the *A. pleuropneumoniae recR* gene homologue. The RecR protein is involved in the RecF pathway of recombinatorial DNA repair: *recR* mutants are deficient at filling in daughter strand gaps in newly synthesised DNA [Kuzminov (1999) Microbiol Mol Biol Rev 63, pp. 751-813]. Mutations in *recR* delay induction of the SOS response in *E. coli* and such mutants

- 35 -

are sensitive to UV-irradiation and mitomycin C [Keller (2001) *Mutat Res* 486, pp. 21-29].

In strain 26A10, the transposon has inserted in a gene with extensive homology to
5 *thrC* of *H. influenzae*. The *thrC* gene encodes threonine synthase, the final enzyme
in the biosynthetic pathway leading to the production of threonine (Patte (1996)
Biosynthesis of threonine and lysine. In *Escherichia coli* and *Salmonella* (Vol. 1)
(Neidhardt, F.C. et al., eds), pp. 408-433, ASM Press). Mutations in a
Streptococcus pneumoniae *thrC* homologue attenuate the virulence of this organism
10 in a murine model of pneumoniae [Lau (2001) *Mol Microbiol* 40, pp. 555-571].

In strain 26D12, the transposon has inactivated a GMP synthase, *guaA*, gene
homologue. GMP synthase catalyses the synthesis of GMP from XMP as part of the
purine biosynthetic pathway. Mutations in the *guaBA* operon attenuate the virulence
15 of a variety of enteric pathogens including *E. coli*, *S. flexneri*, and *S. typhi*, and a
 Δ *guaBA* *S. typhi* derivative shows promise as a live attenuated vector [Wang (2001)
Infect Immun 69, pp. 4734-4741; Noriega (1996) *Infect Immun* 64, 3055-3061;
Russo (1996) *Mol Microbiol* 22, pp. 217-229]. Moreover, previous STM screens in
Streptococcus agalactiae and *P. multocida* have implicated *guaA* and *guaB*,
20 respectively, in growth *in vivo* and in pathogenesis [Jones (2000) *Mol Microbiol* 37,
pp. 1444-1455; Fuller (2000) *Microb Pathog* 29, pp. 39-51].

Mutant 27A12 contains a transposon insertion in a gene previously identified in *A.*
pleuropneumoniae as *tonB* (Tonpitak et al., *Infect Immun* 68: 1164-1170 2000)
25 (now referred to as *tonB1*). This gene is found immediately upstream of, and is be
co-transcribed with, *exbB*, *exbD*, and the transferrin binding protein (*tbp*) genes. In
contrast, strain 0F6 contains a transposon insertion in an ORF encoding a protein
with homology to TonB proteins from *P. multocida* and *Haemophilus sp.* (now
designated *tonB2*). Moreover, sequence analysis of the region upstream from the
30 transposon insertion in 0F6 revealed the presence of distinct *exbB* and *exbD* gene
homologues, suggesting that *A. pleuropneumoniae*, in common with other bacterial
pathogens including *V. cholerae* and *P. aeruginosa*, possesses two independent

TonB systems (Occhino *et al.*, Mol Microbiol 29: 1493-1507 1998; Zhao and Poole, FEMS Microbiol Lett 184: 127-132 2000).

Strain 35D11 contains an insertion in a gene homologous to *H. influenzae dsbA*.

- 5 DsbA is a small periplasmic protein and a member of the thioredoxin superfamily [Debarbieux (1999) Cell 99, pp.117-119]. Mutations in *dsbA* are pleiotropic, affecting the production of a variety of translocated proteins including bacterial virulence factors, components of type III secretion machinery, and c-type cytochromes including NAP [Yu and Kroll(1999) Microbes Infect 1, pp. 1221-1228]. Mutations in
- 10 *dsbA* and *dsbB* have been implicated in the virulence of *Shigella flexneri* [Yu (1998) Infect Immun 66, 3909-3917] and *P. multocida* [Fuller (2000) Microb Pathog 29, pp. 25-38], respectively.

- In strain 26C3, the transposon has inactivated a glutamyl-tRNA reductase, *hemA*,
- 15 gene homologue while in strain 26D5 the transposon has inserted in a putative uroporphyrinogen decarboxylase *uroD/hemE* gene homologue. Glutamyl-tRNA reductase catalyses the reduction of glutamate to glutamate 1-semialdehyde, the first committed step unique to the formation of δ -aminolevulinate (ALA) from glutamate. Downstream from ALA formation, uroporphyrinogen decarboxylase
- 20 catalyses the decarboxylation of uroporphyrinogen III to yield coproporphyrinogen, the first step in the conversion of uroporphyrinogen III to protoheme via protoporphyrin IX. Hemes, including protoheme, are key components of the electron transfer apparatus and in addition play important roles as enzyme prosthetic groups in mineral nutrition and oxidative catalysis (Beale, Biosynthesis of hemes. In
- 25 *Escherichia coli and Salmonella* (Vol. 1) (Neidhardt, F.C. et al., eds), pp. 408-433, ASM Press).

- In strain 15A11, the transposon has inserted into a gene homologous to *P. multocida visC*. The protein encoded by *visC* encodes a putative monooxygenase
- 30 belonging to the UbiH/CoQ6 family. UbiH is required for the biosynthesis of ubiquinone [Nakahigashi (1992) J. Bacteriol. 174, pp. 7352-7359], a prenylated benzoquinone that functions in the respiratory electron chain in the plasma

- 37 -

membrane of prokaryotes. Ubiquinone and protoheme also function in the formation of disulfide bonds in periplasmic proteins by facilitating the oxidation of DsbA by DsbB [Kobayashi (1997) Proc Natl Acad Sci USA 94, pp. 11857-11862].

- 5 Strain 29A10 contains a transposon insertion in a gene homologous to *prfC* of *H. influenzae*. The *prfC* gene encodes peptide chain release factor 3 (RF3), a GTPase that in the presence of GTP catalyses the removal of RF1 and RF2 from the ribosome after translation termination [Freistroffer (1997) EMBO J 16 4126-4133]. The efficient recycling of RF1 and RF2 by RF3-GTP, although dispensable for
10 viability in prokaryotes, is required for maximum growth rate [Kisselev (2000) Trends Biochem Sci 25, pp. 561-566].

- In strains 26A6 and 33B7 the transposon has inserted in genes with homology to the *trmH* family of tRNA/rRNA methyltransferases. The interrupted ORF in strain 26A3
15 shows greatest homology to *H. influenzae yibK*, while that in strain 33B7 shows most similarity to *yjfh* of *H. influenzae*.

(iii) Regulation

- 20 Virulence genes involved in environmental sensing and coordinate regulation were identified in this screen. The *A. pleuropneumoniae* homologue of the ferric uptake regulator, *fur*, was found to be inactivated in strain 6C12. Fur or Fur-like proteins have been shown to regulate virulence factor expression in a variety of pathogens including *E. coli* (Shiga-like toxin), *Corynebacterium diphtheriae* (diphtheria toxin), and
25 *Pseudomonas aeruginosa* (exotoxin A) [Prince (1991) Mol. Microbiol 5 pp.2823-2831; Schmitt (1991) Infect Immun 59, pp. 1899-1904; Calderwood (1987) J. Bacteriol 169, pp. 4759-4764]. Strains 21D3 and 19B10 contain transposon insertions in the *A. pleuropneumoniae rpoE* and upstream *mclA* (*rseA*) gene homologues, respectively. The *rpoE* encoded sigma factor, σ^E /Sigma-24, is a
30 member of the extracytoplasmic function subfamily of sigma factors that function as effector molecules in response to extracytoplasmic stimuli including heat shock and oxidative stress [Raina (1995) EMBO J 14, pp. 1043-1055; Rouviere (1995) EMBO

- 38 -

J. 14 1032-1042; Ades (1999) Genes Dev 13, pp. 2449-2461; Dartigalongue (2001) J Biol Chem 276, pp. 20866 - 20875]. In *S. typhimurium*, σ^E is an important determinant of virulence and immunogenicity [Humphreys (1999) Infect Immun 67, pp. 1560-1568]. MclA (RseA) is an inner membrane protein that acts as a σ^E -
5 specific anti- σ factor. MclA (RseA) is rapidly degraded in response to extracytoplasmic stress resulting in increased σ^E concentration and initiation of the stress response [Ades (1999) Genes Dev 13, pp. 2449-2461]. Finally, insertions in the *A. pleuropneumoniae* quorum sensing *luxS* homologue (strain 26D3) were observed to attenuate *A. pleuropneumoniae* virulence. Recently, the *E. coli luxS*
10 homologue has been implicated in the control of intestinal colonisation factors encoded by the locus of enterocyte effacement pathogenicity island in both EHEC and EPEC [Sperandio (2001) J Bacteriol 183, pp. 5187-5197; Sperandio (1999) Proc Natl Acad Sci USA 96, pp. 15196 - 15201].

15 (iv) Transport

The *A. pleuropneumoniae* gene *aopA* is inactivated in strain 23C9. The *aopA* gene encodes a 48 kDa immunogenic outer membrane protein that is common to all serotypes of *A. pleuropneumoniae* tested [Cruz (1996) Infect Immun 64 pp. 83-90].
20 Interestingly, AopA is highly homologous (75% identity, 84% similarity) to Nqr1 of *H. influenzae* (NqrA of *Vibrio alginolyticus*), encoding the alpha chain of the sodium-translocating NADH-ubiquinone oxidoreductase (NQR) complex [Hayashi (1996) FEBS Lett 381 pp. 174-176; Beattie (1994) FEBS Lett 356 pp. 333-338]. The NQR enzyme is a respiration-linked Na^+ pump establishing an electrochemical gradient
25 of sodium ions across the membrane. The resultant sodium motive force can be used for solute transport, ATP synthesis, and flagellar rotation. This alternative energy coupling of sodium ions rather than protons enables the bacteria to maintain a cytoplasmic pH near neutrality in an alkaline environment. The NQR enzyme has been most extensively studied in *V. alginolyticus* where it is thought to be involved
30 in pH and ion homeostasis [Beattie (1994) FEBS Lett 356 pp. 333-338; Unemoto (1993) J. Bioenerg Biomembr 25 pp. 385-391]. In *Vibrio cholerae*, the NQR complex has been implicated in the regulation of virulence factor expression via its effects on

ToxT expression [Hase (1999) Proc Natl Acad Sci USA 96 pp. 3183-3187].

Components of several different putative ABC transport systems were identified as necessary for virulence of *A. pleuropneumoniae*. ABC transport systems are involved in the transport (uptake or efflux) of a diverse array of macromolecules across the cytoplasmic membrane of bacteria and eukaryotes. These systems usually consist of three basic parts: one or two ATPases, one or two integral membrane proteins and a substrate-specific binding protein. Strains 13B12, 0C5, 19D1, and 24A4 contain transposon insertions in the ATPase component of ABC transporters. The gene inactivated in strain 0C5 encodes a protein with significant homology to MglA of prokaryotic galactose transporters (Richarme *et al.*, J Biol Chem 268: 9473-9437, 1993). The *in vivo* CI of this mutant indicates limited availability of certain sugars within the respiratory tract environment. The interrupted ORFs in strains 19D1 and 24A4 are homologous to hypothetical ATPases from transport systems of unknown specificity in *P. multocida* (PM1728 and PM0996, respectively). In strain 20D10, the transposon has inactivated a gene with extensive homology to *znuA* of *H. ducreyi* and *pzp1* of *H. influenzae* (Lewis *et al.*, Infect Immun 67: 5060-5068, 1999; Lu *et al.*, J Biol Chem 272: 29033-29038 1997 and FEMS Microbiol Lett 165: 129-137 1998). ZnuA (PZP1) is a periplasmic zinc-binding protein that plays a key role in zinc uptake. Inactivation of the *znuA* gene in *H. ducreyi* caused a significant decrease in virulence in the rabbit model for experimental chancroid (Lewis *et al.*, Infect Immun 67: 5060-5068, 1999). In strain 0D6 the transposon has inserted in a gene encoding a protein with homology to putative integral membrane proteins from *P. multocida* (PM0997) and *N. meningitidis* (NMB0549). In *P. multocida* PM0997 is located immediately upstream from the ATPase inactivated in strain 24A4 suggesting that they are part of the same transport system (May *et al.*, Proc Natl Acad Sci U S A 98: 3460-3465 2001). This gene was also identified by Fuller *et al.* (Fuller *et al.*, Microb Pathog 29: 39-51 2000) as *apvD*, the predicted product of which shows homology with the macrolide-specific ABC-type efflux protein MacA (Kobayashi *et al.*, J Bacteriol 183: 5639-5644 2001). In mutant 9D10, the disrupted gene sequence encodes a protein with homology to CorC which mediates both influx and efflux of magnesium as well as cobalt efflux

(Gibson et al., Mol Microbiol., 5: pgs 2753-2762,[1991]).

(v) Stress

- 5 In strain 13A3, the transposon has inserted in a *dnaJ* gene homologue. DnaJ is an essential component of bacterial Hsp70 chaperone systems where it functions as a co-chaperone, providing substrate specificity to its Hsp70 partner, DnaK [Rudiger (2001) EMBO J 20 pp. 1042-1050]. In addition to their fundamental roles in protein folding and translocation, DnaK/DnaJ constitute the primary stress-sensing and
- 10 transduction system of the *E. coli* heat shock response [Tomoyasu (1998) Mol Microbiol 30 pp.567-581] where they modulate the induction of the heat shock response by altering the stability of the heat shock sigma factor σ^{32} . Significantly, mutations in DnaK have previously been shown to attenuate *A. pleuropneumoniae* virulence and to decrease the survival of *Brucella suis* in human macrophage-like
- 15 cell lines [Fuller (2000) Microb Pathog 29 pp. 39-51; Kohler (1996) Mol Microbiol 20 pp. 701-712].

Strain 26B6 contains an insertion in a *htpG* gene homologue. HtpG is a heat shock-induced molecular chaperone that, in *E. coli*, contributes to the correct folding of

20 cytoplasmic proteins in mildly stressed cells [Thomas (2000) Mol Microbiol 36 1360-1370]. HtpG does not appear to associate stably with partner proteins and little is known about its mechanism of action. It has been suggested that HtpG serves as a holder chaperone, transiently maintaining a subset of de novo synthesised proteins in a conformation that is accessible to DnaK/DnaJ [Freeman (1996) EMBO

25 J 15 pp.2969-2979].

Strain 13D8 contains a transposon insertion in a *lon* gene homologue. Lon (also called protease La) is a heat shock-inducible, ATP-dependent serine protease that plays a major role in the elimination of abnormally folded proteins [Gottesman (1996)

30 Annu Rev Genet 30 465-506; Suzuki (1997) Trend Biochem Sci 22 pp.118-123]. In addition to its demonstrated role as a stress response protease, Lon also functions as a pleiotropic regulator of gene expression by degrading unstable regulatory

- 41 -

proteins including RcsA, a positive regulator of capsule synthesis [Keenleyside (1992) J Bacteriol 174 pp. 8-16] and Sula, an inhibitor of cell division and component of the *E. coli* SOS response [Mizusawa (1983) Proc Natl Acad Sci USA 80 pp. 358-362]. Recent studies in *Brucella abortus* have demonstrated that Lon is
5 required for survival in murine macrophages and wild-type virulence in the mouse model of infection [Robertson (2000) Mol Microbiol 35: 577-588].

Strain 13C1 carries a transposon insertion in a *prc* gene homologue. Prc is a periplasmic protease whose natural substrates appear to be membrane proteins
10 including TonB [Gottesman (1996) Annu Rev Genet 30 pp.465-506]. It has been speculated that Prc functions as a chaperone involved in the folding and turnover of proteins in the periplasmic space [Bass (1996) J Bacteriol 178 pp.1154-1161].

CLAIMS

1. An attenuated *Actinobacillus pleuropneumoniae* bacterium.
- 5 2. An attenuated *Actinobacillus pleuropneumoniae* bacterium having a mutation in a gene required for bacterial virulence.
3. An attenuated *Actinobacillus pleuropneumoniae* bacterium having a mutation
10 in a gene which comprises a nucleotide sequence selected from the group consisting of SEQ ID NO.:1-56.
4. An attenuated *Actinobacillus pleuropneumoniae* bacterium having a plurality of mutations, occurring within a single gene or within different genes.
- 15 5. A composition containing an attenuated *A. pleuropneumoniae* bacterium according to any previous claim.
6. A composition according to Claim 5, comprising a plurality of different
20 attenuated *A. pleuropneumoniae* bacteria, having different mutations in the same virulence gene and/or bacteria having similar, or different, mutations in two or more different genes.
7. A composition according to any one of Claims 5 or 6, further comprising one
25 or more pharmacologically acceptable adjuvants, diluents, carriers, vehicles and/or excipients.
8. A composition according to any of Claims 5 -7, which is packaged in a form
30 suitable for administration by intravenous, intradermal, intramuscular, intramammary, intraperitoneal and/or subcutaneous injection, and/or by oral, sublingual, nasal, anal or vaginal delivery.

- 43 -

9. A composition according to any of Claims 5 -8, which is selected from the group consisting of an immunogenic composition, a therapeutic (e.g. prophylactic) composition and a vaccine.
- 5 10. A composition according to Claim 9, wherein the composition is a vaccine whose administration to an animal confers a degree of cross-protection.
11. Use of an attenuated *A. pleuropneumoniae* bacterium according to any of Claims 1-4 in the manufacture of a medicament for preventing or alleviating
10 an infection of an animal with *A. pleuropneumoniae*.
12. Use of an attenuated *A. pleuropneumoniae* bacterium according to any of Claims 1-4 in the manufacture of a medicament for preventing or alleviating symptoms associated with *A. pleuropneumoniae* infection, such as the
15 prophylactic protection of swine against porcine pleuropneumonia.
13. An isolated polynucleotide encoding a gene product which is naturally involved in (e.g. required for) the virulence of *A. pleuropneumoniae*.
- 20 14. An isolated polynucleotide encoding a gene product which is not naturally found in *A. pleuropneumoniae*, but whose expression therein is capable of modulating (e.g. of decreasing) the virulence of that bacterium.
15. An isolated polynucleotide which is not naturally found in *A. pleuropneumoniae* but which is capable of modulating the virulence of that bacterium by its direct interaction with *A. pleuropneumoniae* virulence genes
25 or gene products.
16. An isolated polynucleotide comprising: (a) a nucleotide sequence selected from the group consisting of SEQ ID NO.: 1-56; (b) a nucleotide sequence encoding the polypeptide which is encoded by the nucleotide sequence
30 recited in (a); (c) a nucleotide sequence which hybridizes to the nucleotide

- 44 -

sequence of (a) and/or (b), or to its complement, under conditions of moderate to high stringency; or (d) a fragment of any one of the nucleotide sequences of (a)-(c), which fragment retains an immunological property and/or a biological activity of the recited nucleotide sequence of (a)-(c).

5

17. A vector comprising a polynucleotide according to any of Claims 13-16.

18. A host cell containing a polynucleotide or vector according to Claims 13-17.

10 19. An attenuated bacterium containing a mutation in a gene comprising a nucleotide sequence which is capable of hybridising to any one of the nucleotide sequences defined by SEQ ID NO:1-56, under conditions of moderate to high stringency.

15 20. An attenuated bacterium according to Claim 19, having a plurality of mutations, occurring within a single gene or within different genes.

21. A composition containing a bacterium according to Claims 19 or 20.

20 22. A composition according to Claim 21, comprising a plurality of different attenuated bacteria, having different mutations in the same virulence gene and/or bacteria having similar, or different, mutations in two or more different genes.

25 23. A composition according to any one of Claims 21 or 22, further comprising one or more pharmacologically acceptable adjuvants, diluents, carriers, vehicles and/or excipients.

30 24. A composition according to any of Claims 21-23, which is packaged in a form suitable for administration by intravenous, intradermal, intramuscular, intramammary, intraperitoneal and/or subcutaneous injection, and/or by oral, sublingual, nasal, anal or vaginal delivery.

- 45 -

25. A composition according to any of Claims 21-24, which is selected from the group consisting of an immunogenic composition, a therapeutic (e.g. prophylactic) composition and a vaccine.
- 5
26. A composition according to Claim 25, wherein the composition is a vaccine whose administration to an animal confers a degree of cross-protection.
- 10
27. Use of a bacterium according to Claims 19 or 20 in the manufacture of a medicament for the therapeutic treatment or prophylactic protection of an animal against infection by the corresponding wild-type bacterium (or a different strain or serotype thereof).
- 15
28. An isolated *A. pleuropneumoniae* virulence polypeptide.
- 20
29. A method of producing a virulence polypeptide according to Claim 28, comprising the steps of: (i) culturing a host cell according to Claim 18 under conditions that permit the expression of the polypeptide; and (ii) recovering and optionally isolating the expressed polypeptide from the host cell, or from its surrounding medium.
- 30
30. A virulence polypeptide encoded by a polynucleotide according to any of Claims 13-16.
- 25
31. A composition comprising a polypeptide according to Claim 28 or 30.
32. A composition according to Claim 31, further comprising one or more pharmacologically acceptable adjuvants, diluents, carriers, vehicles and/or excipients.
- 30
33. An antibody which specifically recognizes a polynucleotide or polypeptide according to any of Claims 13-16 and Claim 28 or 30.

- 46 -

34. A method for identifying an anti-bacterial agent which is capable of modulating the function of an *A. pleuropneumoniae* virulence gene of the present invention, or of a homologous gene in a related species.
- 5
35. A method according to Claim 34, comprising screening potential agents for their ability to interfere with the expression and/or biological activity in a host bacterium of the gene products encoded by the nucleotide sequences set forth in any one of SEQ ID NO.:1-56.
- 10
36. An agent identified by the method of Claims 34 or 35.
37. A method of modulating the transcription of such virulence genes through the use of oligonucleotide-directed triplet helix formation.
- 15
38. A composition comprising an anti-bacterial agent according to Claim 36.
39. A method of treating an animal suffering from a *Pasteurellaceae* (e.g. an *A. pleuropneumoniae*) infection by administration of an anti-bacterial agent or composition according to any of Claims 36 or 38.
- 20
40. Use of an agent or composition according to Claims 36 or 38 in the manufacture of a medicament for the treatment of a *Pasteurellaceae* infection and/or porcine pleuropneumonia.
- 25

1/3

TABLE I

Class	Strain	Gene	Similarity to:		Known or Putative Function:	In vitro CI:	In vivo CI:
			%	Span			
Cell Surface	9C2	cpxC			capsular polysaccharide export inner membrane	1.020	3.88E-03
	26A9						
		lcbB (Nm)	37(50)	82	LPS or capsule biosynthesis	1.068	
	9B7	galU			LPS core biosynthesis	1.750	
	25B7	rfbU			LPS O-antigen biosynthesis	0.0014	
	10B11	mlc	100	15	LPS O-antigen biosynthesis	0.232	
	12D5	rfbN			LPS O-antigen biosynthesis	0.024	
	21B8	rfbP			LPS O-antigen biosynthesis	0.029	
	15A9	hypothetical glycosyltransferase	37(55)	270	gi:18977170 LPS O-antigen biosynthesis	0.739	
	4D4	lppB (Hs)	46(63)	83	lipoprotein B precursor	1.870	
Metabolism	17A4	ompP2 (Hi)	40(55)	237	Outer membrane protein P2 precursor	1.149	
	10B12	adpP (Hi)	61(76)	62	ADP-ribose pyrophosphatase	1.029	
	10A11	argG (Hi)	65(88)	34	arginosuccinate synthase	0.802	
	33C7	atpA (Hi)	89(95)	134	ATP synthase	0.314	
	17B8	ccmH (Hi)	53(77)	166	cytochrome C biogenesis protein	1.100	
	35D11	dsbA (Hi)	63(77)	160	thiol:disulphide interchange protein precursor	1.040	3.43E-04
	26C3	hemA (Pm)	61(74)	394	Glutamyl-tRNA reductase	0.048	
	4B9	moaA (Hi)	67(74)	114	molybdenum cofactor biosynthesis protein	1.150	

2/3

19D5	mtp					AD01696	ATPase	0.200	
29B11		napB (Pm)	55(70)	77		AAK03681	periplasmic nitrate reductase	1.050	1.093
9B5		pnp (Pm)	75(79)	125		AAF68421	polynucleotide phosphorylase	1.180	
0A7		pntB (Hi)	68(77)	458		P43010	NAD(P) transhydrogenase	0.785	
23C9	aopA/nqrA					AAC43631	Na-translocating NADH-ubiquinone oxidoreductase	0.716	
29A10		prfC (Hi)	73(81)	342		P43928	peptide chain release factor	4.670	
29B12		recR (Hi)	81(87)	71		P44712	Recombination protein	3.600	
26A10		thrC (Hi)	88(93)	190		P44503	Threonine synthase	0.867	1.598
0F6		tonB (Hd)	64(74)	288		O51810	Energy transducer	2.488	2.20E-02
27A12	tonB					Y17916	Energy transducer	0.902	1.54
26D5		uroD/hemE (Pm)	88(93)	230		AAK03818	Uroporphyrinogen decarboxylase	NA*	
15A11		visC (Pm)	55(82)	43		AAK03810	monooxygenase	0.684	
26A6		yibK (Hi)	70(84)	127		P44868	probable tRNA/rRNA methyltransferase	0.599	
33B7		yifH (Hi)	77(85)	157		P44906	probable rRNA methylase	0.744	
26D12		guaA (Hi)	83(85)	43		P44335	GMP synthase	1.586	
6C12	Regulatory	fur (Hd)	79(83)	139		P71333	ferric uptake regulator	0.627	2.76E-02
26D3		luxS (Hi)	69(84)	118		P44007	autoinducer-2 production protein	2.063	
19B10		mlcA (Pm)	45(69)	61		AAK03872	negative regulator of rpoE	1.725	6.50E-02
21D3	Stress	rpoE (Hi)	81(90)	189		P44790	Sigma factor E	0.789	0.88

3/3

13A3	dnaJ (Hd)	85(99)	14	P48208	chaperone protein	0.163
26B6	htpG (Ec)	69(82)	368	P10413	Heatshock protein	1.251
13D8	lon (Pm)	74(86)	292	AAK04062	ATP-dependent protease	0.674
13C1	prc (Pm)	65(79)	290	AAK02353	tail specific protease	1.324
22A10	tig (Pm)	50(61)	152	AAK04059	Trigger factor involved in cell division	0.851
9D10	corC (Hi)	66(78)	248	Q57368	Magnesium and cobalt efflux protein	3.380
19D1	Hypothetical ABC (Pm)	79(89)	110	AAK03812	ABC transporter	1.341
0C5	Hypothetical membrane protein (Pm)	81(86)	242	P44884	galactoside ATP transporter	1.80E-02
0D6	Hypothetical ABC (Pm)	56(76)	210	AAK03081	Probable membrane protein	1.268
32A7	yfeB (Pm)	60(73)	370	AAK03080	Probable ABC transporter	0.962
13B12	znuA (Hd)	75(86)	185	AAK02483	iron (III) ATP-binding protein	0.922
35D1	No homology A	71(78)	176	AAF00116	periplasmic zinc ABC transporter	0.450
14D5	No homology B				Unknown	0.953
2D5	Unknown (Pm)	31(52)	124	AAK03268	Unknown	5.34E-03
32A11	Unknown (Pm)	42(59)	327	AAK02354	Unknown	1.245
4C1	Hypothetical protein (Hi)	53(74)	91	P44027	C4-decarboxylate transport protein homologue	0.991
9A4						0.935
						1.110
						1.018

Transport

Unknown

- 1 -

SEQUENCE LISTING

<110> Imperial College Innovations, Ltd.

<120> Bacterial Virulence Genes

<130> MRM/PJG/24342

<150> GB 0228691.2

<151> 2002-12-09

<160> 63

<170> PatentIn version 3.2

<210> 1

<211> 3344

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 1
gaattctaaa ttgagctgcc aatgcttggt gttcgtcaca attcacggtt gccataaaaa 60
attgtgccgg attttcatcc gccaacgggc gtaataatga atccatttcc aatgaagcca 120
cttctctcgg cgagataaaa ttaaacacga cgggcacttg tgtcgccgca ttccacactt 180
cactaaaatt actttcggta acattgacaa aataattcat actcttttcc taatctaaaa 240
aatcggcaaa ttatacttta tttttagtaa gccgtttcaa tcggtaaacc gcttctttcc 300
caaccgtcga aaccgccttt cagctatat acgcgatcaa aacctgttc gactaaaaat 360
tgtgcggtat tacgactgct cagccgtga tagcacatga cgatgaccgg ttcttcataa 420
tccacttcat ctaaaaaacg cccgtagctt tcattagtta aatggaacgc atcttgcgga 480
tggctatagg cataacgacg tccatcacga atatccgcta aagtcgcacc ttcgttttcg 540
attaattccc acgcctgatg cgggctgatc tcagtaaattg tttcactcat atttcatgct 600
caataagaaa aataaaccaa ataaaattaa tcgactatac cataagacgt ttacaaaaat 660
aaacgagaat acctattatt acgagttgaa ttttctgact tacttagtat aattgcaaac 720
cattttcatt atacagaact cactgtttgc ttcttttaga ctgtttccga ggattttatg 780
gaacaaatgc ttgaactttt acaagggtcat gttgattata ttatttttagg cttattacta 840
ttaatgagtg ttgtgttggt atggaaaatt attgaacgcg tacttttcta caaacaattg 900
gatgtgacca aatatgacac gctacaagat ttggaaattg ataccactcg caatttaacc 960
accatttcca ctatcggtgc caacgcccct tatatcggtt tattaggaac cgtattaggg 1020
atcttactta ccttctatca tttagggcat tccggcggtg atattgacgc cgcattccatt 1080

- 2 -

atggttcacc tttcgcttgc attaaaagca accgcagccg gtatcttagt cgctattccg 1140
gcaatgatgt tctacagcgg ttttaaccgt aaagtggatg aaagcaaact taaatggcaa 1200
gcgattcaag ctcgtaaagc caatcaataa gcggtcaaat ttcacttatt ttttgcaact 1260
caatcaggct tcttatgaaa aaatttgacg aaattaatat tattcccttt atcgacatta 1320
tgttgggtatt actggctatc gtgttggtaa ccgcttcatt tatttctcaa ggaaaaattc 1380
cggttaatat tccgaaagcg accacaactc aagcgatgaa agcggacgaa ttggcaaaac 1440
ttctgacgat taccgaaaac aacgagtttt atttcaacga tcagccgatt accaaagaag 1500
cactcacgag cgagattgca acttgggata aaacccaaaa agtaacctta aaagtggacg 1560
gtgcggtagc ctttgaaaaa tttgtcgaac tgactgatgt tctctctgcg aatgaaatta 1620
agaatgtcgc tatcgtagcc aaaaaagata cctcgaagaa ataggatacg agtatgaaga 1680
aaaaacattc tcgtatcggc ttaaccggct ccattcttat ccataccgct attttcggcg 1740
gtttagcctc tatggtaacc cattctcatt ccgatgattt accccaagaa gaaacgatgt 1800
ctatggagtt agtcgccgca cttttggaac aacctcaagt tgccgtcgca caagaagagc 1860
cggcaccgcc ggagccggag aaagtcgaag tcgagccgga accggagcct gaagcggag 1920
ctattccaga acttaaaccct cagcctaagc cgaaagaaaa accgaaggaa aagcctaagg 1980
aaaaacccaa accgaaagaa ccgccaaagc ctaaagaaaa agaaaaacct aaaaaagaga 2040
aagtaaaaga taaaccgatt aaggcgtagt aaaaaggctc tgaagcaaaa caaggtattg 2100
tcgccaaagc gattcctaatt gcggtacaag gcactcaatt acgtgcaggc attccaaacg 2160
gtaaaccgga aggtaatccg aacggctctt ccgccaacgg ttcacaaaac ggtgcggtag 2220
gcggtagtgg tagcggagct tccggaagtg aaatcggtgc gtataaagcg gcattacaac 2280
gtgcattaca acgccgagcc aataacgctt atccgactcg agaaaaaatg atgcgcaaaa 2340
cgggcgtggt tactatcggc tttaccgtat cctcttcggc cgagttaatc aatgtcaaag 2400
tgtaaacag ttcgggtaac ggtaatcttg ataatgcggc ggtcaaagcg gcacaaagca 2460
cgaaagtttc accgccgcgc gcgggattcc cgagtaatgt gaccgttcgc gtgaaattct 2520
cgattgaata aatcttgta ataagctccc gtaagggagc ttatttttac ttaagccaag 2580
cggtcgtttt tagcttactt gttgcaaaaa atcgacaaaa gataaccgct tgcctaaagc 2640
ggagtgccta agtaaaataa accgtttcta tttttattat acaaattgag gaaaatataa 2700
tgtttggaag aggcggctta ggcggtttaa tgaaacaagc tcagcaaagc caagagcgta 2760

- 3 -

tgcagaaaat gcaagaagaa atcgcacagc ttgaagtcac cggcgaatcc ggtgcggggtt 2820
 tagtcaaagt aacgatcaat ggcgcacata attgccgtcg tatcgaaatc gatccgtcat 2880
 taatggaaga cgataaagag atggtggaag atttagtcgc tgccgcattc aatgatgccg 2940
 ttcgccgtgc ggaagaaatg caaaaagaaa aaatggcaag cgtgaccgcc ggcatgcaat 3000
 taccgccggg catgaaattc ccattctaatt ttagagataa tggatagttc gctttattgc 3060
 ggctatccat tattaatttt caactatccg gtctattaaa gcaaattagc cctttactcg 3120
 aaaatctgat ggaagacata agagccctac gtgcattacc cggcgtcggg ccgaaatccg 3180
 cacaacgtat ggcgtatcat ttattgcaac gcaatcgttc cggcgggtatc aatttatcca 3240
 aagccttaaa tgaagcgatg acgcatatcg gtcattgccg ttcttgccgt acttttaccg 3300
 aagaagacga atgcaatatt gttgatgcgc tggcagtggt cctg 3344

<210> 2
 <211> 1080
 <212> DNA
 <213> Actinobacillus pleuropneumoniae

<400> 2
 ttgaaagttt caccatatat tggctcaagt tattattcat ctaaataac agattattac 60
 tttggtatta aacaatccga attaggtaat aaaattacat ccgtatataa acctaaagca 120
 gcttatgcaa cacacatagg tattaatact gattatgctt tcacgaacaa tcttgccatg 180
 gggtttatctg tcgggttgga taaatattct aaagaaatta agcaatctcc tatcataaaa 240
 cgagactctc aattttacttc atctcttagc ctttattata agttctaaaa tagaatattc 300
 tagggagaat actcattctt tatctttata aagttaattg tttctccctg tttctatatt 360
 atttagttac ttgttcaaaa gctacattgg ttattttgtc attttataaa agataataag 420
 gtggttattt tgaaaattaa gaaatatatt aaatataccc tattttacttt ccttttaggc 480
 atatcatatt tatatttttg gggcgaaaac gaaaattatc aagagattat ttttcacgtc 540
 gaacgaggaa atattcaaaa aacagttatt gctagcggca cattgcaagc gactgaacaa 600
 gtagatattg gtgcacaagt atctgggcag attaagcata ttttagtaca agaaggacag 660
 aagggttaaaa aaggtgagct attagctgta attgatccac gtctggctga aacggaatta 720
 aaactagcaa aagctgagct agcaaatgct tctgctaatt tggatacaaa aaaaattaat 780
 cttaagcaac tgcaatcaga ttgggaacgt catcaacgtt tgatacgaac caatgcgaca 840
 agccaaaagg aaacagaaga agcaaaaagt agattaaata cggccaaagc agaacttcaa 900

- 4 -

attgcgcaaa ataatctaga tatcgctaaa atcagagtgg aaaaagctga aaccgaacta 960
ggatatacag aaattcgttc tccacttgat gcaacagtaa tttcagtatt tgcgcaaaat 1020
ggtcaaactt tagtcaccac ccaacaagta ccagtgtga tgaaattagc taatattgat 1080

<210> 3
<211> 582
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 3
cgggtattat ttatatttcg cacaaaatgg atgaaatctt caaaatttgt gacgaaatta 60
caatcttacg tgacggtaaa tgggtcaata cgggtgcgat taaagacacc tcaatggaac 120
aaatcgtttc gatgatggta ggtcgtgaac tgacccaacg tttcccggaa aaaaccaata 180
agccgaaaga aaccgtactc gtggtcgaac atttaaccgc taaaaatcag ccgctctattc 240
aagatgttag ctttgaattg cgtaaaggcg aagtgttggg tatcgccggc ttggtcgggtg 300
caaaacgtac cgatattgtc gaaacgattt tcgggtgtgcg tgaaaaagcc ggcggaacta 360
ttaccttaaa cggcaaagcg gtaacaatc gtaatgcgtt tgaagcaatc aataacgggtt 420
ttgcgctggg tactgaagaa cgccgctcaa ccggtattta tgcgaatctc agcatcgaat 480
tccactcggt gatttcaa atgaaatctt atttaggtaa gttcggctta ctcagcaata 540
aaaaaatgaa aagcgatacc cagtgtgat gaatccccta at 582

<210> 4
<211> 1264
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 4
ggactttcta aacacgaacg gccaaaagcg gggtgttggg ccggtatcgt cgggatggcg 60
attgcgtag tgcgaactat cttcgggtcc gcaatcacia ggtacgcttt ggatttaatc 120
gcaatggcaa tcggcgggatt tatcgggtgtg agaaaagccg taaaagttga aatgacggaa 180
atgccggaac tagtggcgat tctacatagc tttgtcgggt tagctgcggg attagtcggg 240
tttaacagct acggtttaca cgtagatgcg attccaccgg caaacttaga tgaagtggca 300
ctagcggcat tccaagccga acaagcgata ctcgctaaca ttcataatgt tgaagtgttc 360
ctcggtatct ttatcgggtgc ggtaacattc tccggttcat tagtggcggt cggtaaatta 420
agcggtaa at tattcgggtcg taaagtgtct tcggctgcat taaatattcc gcataaacat 480

- 5 -

aaatggaact tagcggcatt aatcgtttct gcgttattaa tgggtggtatt cctaaataat 540
 ccgcacaata ttttcctgt gttgattatg acggtaatcg cattagtatt cggttggcac 600
 ttagtatect ctatcgctgg tgcggatatg ccggtagtgg tttcaatggt gaactcatat 660
 tcaggttggg cggcagcggc agccggattc atcagtgcta acaacgactt attaattgtg 720
 actggtgctg taggggttca tcagcgcgat tctttcttac atcatgggga aagcgggaac 780
 cgctcattta tcagcgtgat tgcaggcggc ttcggtacgg aagttaaagc aagctcaggt 840
 gatgaagaac aaggtgaaca ccgtgaaacc accgcagaag aagtggcggg aatgctgaaa 900
 aatgcaagtt ctgtaatcat cactccggga tacggtatgg cggtggcggc agcacaatat 960
 ccggttgctg aaatcactgc aaaattacgc gagaaagggtg ttaatgtgctg ttttggtatc 1020
 caccctgttg cgggtcgttt accggggcat atgaacgtat tacttgcaga ggcaaaagtg 1080
 ccttatgatg tcgtgcttga aatggatgaa atcaatgatg atttcgaaga aaccgatgtc 1140
 gtattgggta tcggtgcgaa tgatacggta aaccccgctg cattagacga tccgtcaagt 1200
 ccaattgcag gtatcccgta tttgggaagt gtggaaagca caaaaccgtt atcgtatcaa 1260
 cctt 1264

<210> 5
 <211> 574
 <212> DNA
 <213> *Actinobacillus pleuropneumoniae*

<400> 5
 tacgcaacag gataaaaaat cgttttttaca atcgattttc agcggcttat ttcaatccga 60
 accgaaaaat agagaagact tgggtgaagt aattcgagat tctctggata acgaactgat 120
 cgatagtgat accaaagata tgatcgaagg cgtaatggag atttccgaac tgcgtgtgctg 180
 ggatattatg atacctcgtc cgcaaactcg ttatattgac gccaatcttg atcttaccgc 240
 ttgtgttgat ttaatcattg aatccgctca ctctcgcttt ccggtcattt tagacgacgg 300
 caaagatacc gtattaggta ttttacatgc caaagatctc ttaaaattcc tcagaaccga 360
 ttccgaagag tttgaaatgc caaccattct acgccctgca gtgattgtgc cggaaagtaa 420
 acgggtcgat agaatggtga aagaattccg ctccgaacgc tttcatatgg cgctggtagt 480
 ggacgaattc ggtgcgggtat ccggcttagt cacgattgaa gatattctcg agcaaactcg 540
 cggcgatatt gaagacgaat tcgacgaaga agaa 574

- 6 -

<210> 6
<211> 575
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 6
gatatcgtat cacataagta aagaccgctc gcataagcga agcggttcta atttcatcta 60
aagttttact cgtgtactga cgaagtaatg caaggatttg catcagtttt ctcttgcaatt 120
aatactttat cgccgcgagt ttctaaattt aagcgtacaa caggttcggg atttgaactg 180
cgtaagttga aacgccagtt ttcaaattca acgctgatac cgtctaagggt ttcgacttta 240
ccgtctttat acgcttcttt aacacggtcg atagccgctt tagcatcagt taatttactg 300
ttaatttcac ccggtgacgg gaatttatcc aaacgagcac cgactaatc gcttaacggg 360
ttacctgtcg tacatagtag ttctaacggt aatagccatg gaatcatacc gctatcacag 420
tagaagaaat cacggaaata atggtgagca gacatttcac caccataaat cgcactctact 480
gcgcgcattt tctctttaat aaacgagtga cccgattttg acatcacgcg ttcgccgccg 540
gcttccgata ctaattcttc cgtattccaa attaa 575

<210> 7
<211> 379
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 7
tactaaacct tctttaccac ctaagataga aacgaacgca ccgaagtcca caacgcgagt 60
tactttacct ttgtagatcg cgttcacttc aacttcagcc acgatattct cgatacgagc 120
cattaccgct ttcgccgat tattatcggg tgcggcgatt ttacgggtac cgtcgtcatc 180
aatatcaatc gaagtaccgg tttcttcggg taatgcgcga attaccgcac cgcctttacc 240
gatcacgtct ttgattttct tcggatcgat cttcatcgta tgaatacgag gcgcaaaatc 300
ggaaatatcg gcacgagggt caggaatcgc ttgttccatc acgcttaaga tgtgcatacg 360
cgcacctttc gcttgattt 379

<210> 8
<211> 876
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 8
attagcagta acagggtgat taacttataa tttatagggg tttttatgaa atcagataaa 60

- 7 -

ccggttgaat gtgtgggttg taacactttt gatgtcggct caatcattga taatagtga 120
cgagatgcga aatttgcaaa agtatatgaa acacaagcgg aagcggaaca agcacttggtg 180
aaattaaccc aaaaagcacg cgatacggaa agcgaaccgt gtgaaatcac cagtgaatt 240
aaagcggtag agggcgggtt tttactggat gcgaatttcc gttttagttg ccaagcggaa 300
gtggtaattt tccaattagg tacacgcgca atccgcgcaa tctaatttta ttaatttgaa 360
aagcggttgg attttgctga aaatttgcaa aaaatgagca aaatccaacc gcttttgttt 420
tcggagaaat tgatgaatcc ttgggtttta ctaggctttg cgattgttat tgaagtgatt 480
ggcagtaatt gcattaaggc aagcgaaggt tttagcaaac cgctaccgac cgtagtggcg 540
atcggcgctt ttgtgatagc gttatattta ttgtcgggtga ttacccaaaac attgccgatt 600
ggatttggtt atgctgtgtg gtcgggtgtc ggtatcgtag tgaccgccat tgtggcatat 660
ttcgctttcg ggcaaaaacc ggatttggtg ggctttatcg gtatgggaat gattattgcc 720
ggcgtgctag taattaactt attctcaaaa gcatctactt aattttgaaa tgtgatacaa 780
gcggttgatt ttcacaagaa ttttgcaaat tttcttcaa aatcaaccgc ttgtttttgc 840
ttaaggctgg tcgccggcta acgcacgagg gaataa 876

<210> 9
<211> 1251
<212> DNA
<213> Actinobacillus pleuropneumoniae

<220>
<221> misc_feature
<222> (489)..(489)
<223> n is a, c, g, or t

<400> 9
agtcacggt atcttcggtt gcggtgacca agaagattat gcggaatatt tctgtgatgc 60
gatgggaacc attcgcgatg tcgttgagca aaacggcgggt gtgattgtcg gacattggcc 120
gacggaaggt tatagctttg aagtatcgca agcgttagtg gacgaaaata catttgctcg 180
tttatgtatt gatgaagatc gccaaccgga attaaccggt gaacgtgtaa accgttggtg 240
taaacagatc tttgatgaga tgtgcttaga tcagtttagca taatgaatat aagagagaga 300
agggtaccaa gttatgtctg aagaaaatgc aaaacttctt aaaagtgtag gtttgaaagt 360
tactgagcct cgtttgacca tccttgcggt aatgcagcaa catcgcgaaac aaatgctaca 420
tttttctgcc gaggatattt ataaaatttt attagagcag ggttccgata tcggtttggc 480

- 8 -

aacggtttnc cgcgtattaa accaatttga agaggtcggt attttacttc gccataactt 540
 tgatgcgaat aaagcggat tgcagcttaa cgtagagcaa gaacacgata atattatctg 600
 tatggattgc ggtaaggat tgcagtttaa agatccggat atcgaacgcc gtcagcgtga 660
 aatcagcgaa cagcacggta tgaaattagc gacgcacagt ttatatctct atgcgaaatg 720
 tagcgatatt tcacattgtg attcttcaaa agataaaaaa taatttatct tatcgttcag 780
 tataaagcag acatataccg aaggttttgc aggccttcgg ttttgtgtta tctaaaggat 840
 atgaaattaa gcggttggtt tgtaaaattt ttagtaaaaa cgaccgctat ctgaaagaga 900
 cctcgattta atgacggata atatttcaca gcctgtagag gccaaaggtc gacagcctcg 960
 taaaatctca cctttttggt tactaccaat cgttgctttc gtgattggcg gattgttatt 1020
 tttccagatc cttaaagagc agggcgaaat gatcacgatt cgtttcaacg aaggcgacgg 1080
 gatcaccgca ggaaaaaccg tcattcgcta ccaaggtttg cagatagggc aagtgaaaaa 1140
 agtctatttt gtagaagatc ttaaaaaagt cgaagtgcaa gcggaagtga atcccgaagc 1200
 caaatccgtg ttacgagaac aaaccaaatt ctggtggtaa aaccgagtcc t 1251

<210> 10

<211> 748

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 10

gattcgattc aatcggtaga aatgccggcg tctatggcat cggctccgtc acggacaatc 60
 gagcaaaata ccgcttataa taatcaaacc gcttatacgc aaccgggtta tagcgtaccg 120
 caacagcctg tggttcaaac tccggtacaa tccgcaccga gctatacaag cgaaagcggc 180
 gccggtagca atatgattgg taattgccga gtggtaagag atgcgttagg tgcaccgggt 240
 tatgcggaaa ttaccaaagg ttgttatacc gatagtagtt atacggtcgg aaaaagcgat 300
 acaatgtatt taatttcgta tcttaccggc caaacgccgg cacaattgc ggcattaaat 360
 aatctcagt tagagagtaa attacacgta ggtcaaatac tgcgtgtaag ataacggtag 420
 gtttattttg ttagtattaa cgacagttgt gctttgccgc tgcgtttta ttcgttttta 480
 gatttttaaag gaaagtaata tgaaaaaggc atttttatta ttgccgttta tggtaagcct 540
 gaccgcttgc ggagcaagtg agaacgcacc gaaagacgat gcggaattgg cgccggggat 600
 tatgcaaccc gtttccggat caggcgcata gacaggaagc tacggttggt cgtcagacgt 660
 tgagtccgca ccgatgccgg cttcaatgac taaataatcg ttttagcata cgaaaggata 720

- 9 -

aattgaacag atgaagaaat catttttt

748

<210> 11

<211> 511

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 11

tgcaacgctt gttacaagaa ggctggcaat tacagccaaa agcggttatcg gacggccccgg 60
cgaaagtgct ttcacaccct gattaccaag gcgaaatcgg tttgattatg ccgtatgaga 120
aaaacttctg cgccagctgc aaccgcctgc gtgtttcggc actcggcaaa ttgcaccttt 180
gcttattcgg cgaggaaggc attgatttgc gagatttact ctcggaagat acccaacaag 240
cgcaattgaa agcacgctta aaagccgcat tacaaggtaa acgggaacat cactatttgc 300
atatcgggtga tagcgggatt cgaaataacc tcgcctcaat cggcggctag tttctctgtt 360
acttttcttt gcgttgccaa agaaaagtaa ccaaaagaaa ggcaacccta cttcacgcgt 420
gttcttcact tagttgaaat ttgcttaacg gaacatttta gattcgcta cggctcaaga 480
aaaatgttcc tacaaattgc aacacgctca g 511

<210> 12

<211> 1218

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 12

tgctaagcat gaagaacgta ttgcgaaaga acctgagttt attacgttaa acgaagatat 60
tgcaatccgt aaagaaagag gcgctcgcaa gtattcgtca ctgaatctgg aagagcgttt 120
gaaagaagat cgtgccgacg aagcgaaacg tctgaaagat ctgaatgcac gctttgcaag 180
ggaagggaaa aaagcgatta agaattattga cgccttaccg aaagactatg aagcgccgga 240
ctttttctta aaagaagctg aaaaaatgat gggtgattgg ttagaaattg ataagaagtc 300
ataaaatagc ttataatgta tttaaattagc tgccgcttaa tgaaagttag gcggtttgtt 360
tttattgata ttttataatc tcggagctaa ggatttttat atgagtaagg cgaaaacctt 420
caaattactg ccgtagtaaa tgctttcaag tgctggttta gccgaaacta atgcaactca 480
tcttcaggct gcatcaacag aaaacgcaac ggtaaatcat gcgacatcgg atgcaatttt 540
accccagcta agtttttagcg ctcagcaggc tagagcggct gaacttgcaa aacgtgcgga 600
ttatgttttt gagcaagagc agattcgttt ggaagaagaa cgtaaattgc aagaagcgg 660

- 10 -

gttgaaagta aagcaaacgg tcggagataa tcagttatta ctaactaaat cggttgctaa 720
aatttatttg gataacgatt atgcaagtat gtggaatgac aagcatgcgg agaagcaatt 780
cctcaaggaa tacgcattat ttgccgcaag cggcgatatca agcaaatcgg ccaaagcatt 840
acaacagatt ttaaatacgc cggaagggtt gggcagagat atcttattaa ccgacgggtt 900
cttagattat ctctattaca ataaaaacgt gtataaaaat gcgaatcaat gggtatacaa 960
ccttggcaac cttggcagct atagccctaa atcacctagc tcggaacaaa taaatcaatg 1020
ggcggaaatcg actaagaacg gtgattcggc tcacttcggg gcaaatttag tgcttcgtaa 1080
tcatatttat caagaaacgg ggcaacgcgt cttagcgatg tctgccggcg ggaatacggg 1140
gaaagtagca aaagcaaaga aaacaaaaac gcctgagctg gcaacggcaa ccggtaacga 1200
tacgttctat aaattagc 1218

<210> 13
<211> 712
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 13
attctaggtc gtcagtctga gaatttaact cgtgcatggg catatgcgat ggcgttaggt 60
gtggaagata aagtaaaaac cgcactcttt gaagcggcgc aaaaagatgc aatgaaatca 120
atggacgata ttaaagcggg atttactgca aacggcgtaa gtgcagcggg ttttgataat 180
ggcattaata gctttgcggg aaatggtttg gtaaacaac aagtacaatt agcagaagat 240
tttaaaattc gcggcgtagc ggcgtttttc ataaacggac agtaccaaatt caatttgga 300
ggcttttgccg attccgcac aaccaacgaa tttgtgaaac gttatgtaga agcgggtgact 360
tttttaatta aaaagtaaatt taagggcata gtagacaaaa tggttgctat ttttgaaaa 420
actatgccaa gtggacaaag tggaggctaa atagtatttt ttattttatt tagccactct 480
ttttatttaa aaaatccttt ataaacataa cattatgtga ctacttaatt ccattatgat 540
tatttaattt ccgcttcagt tcactaaata atccttcag tctatttgct gtcttttcaa 600
tatttaattc cgggtatttt tcataagtaa aaatataatc catataacgt ttaatactcg 660
cataagcact tctcacattt caatgtttat agggaaaata accctgctca tt 712

<210> 14
<211> 496
<212> DNA
<213> Actinobacillus pleuropneumoniae

- 11 -

<400> 14
 tgcttagttt agacggtgta ccggcaatta aagcgattgt cgatgcaacg gaaaaacatg 60
 ataacgatga aaagcacgag catgatcacg accataagga cgatcataaa catgaccacg 120
 acgatcataa acacgaccat gcagggcatg atcatcacca tgatcacgaa gggcatagcc 180
 atgataaaga ttggcatatt tggttctcac cggaagcaag ccttgccgcg gcggaacaaa 240
 tcgcagcacg tctaagcgca caattaccgg aacaaaaagc gaaaattgcg gaaaaccttg 300
 caacatttaa agcaaattta accgctaaaa acgaacaaat tcgcaatcaa ttagcagcag 360
 taaaaggtaa aggttattat actttccatg atgcttacgg ctatttcgaa cgtgcttacg 420
 gattaacctc attagggtcg ttacgatta acccgagcgt agcgccgggg gcgaaaacgt 480
 taagcgtaat taagaa 496

<210> 15
 <211> 408
 <212> DNA
 <213> Actinobacillus pleuropneumoniae

<400> 15
 agctctacat catctaaata accgaattca gcagcaaaaa gaactaatgc ttgttcgctt 60
 accagcattg gagcaaattg tttttgttta agtaattccg tcaacttttg accgtgagaa 120
 agctgtttac gagtcgcac atctaaatcg gaagcaaatt gagcaaacgc cgctaattca 180
 cgatactgag ctaatgcggt acggataccg ccagataatt tcttgatagc ttagtattgc 240
 gccgcagaac ctacacgaga tacggaaata cccgggttta ccgcaggacg aatacctgag 300
 ttaaataaac ttgactctaa gaaaatctga ccgtcagtaa tagaaattac gtttgtcgga 360
 acgaaagccg atacgtcacc cgcttggtgc tcgataatcg gaatgcag 408

<210> 16
 <211> 476
 <212> DNA
 <213> Actinobacillus pleuropneumoniae

<400> 16
 cgcttaaccc cgttactaaa tgagttcaac gtttaggtat ttccgttcag caagtaaacc 60
 gccaaacatt ggataacaaa gcgcaagggtg aagttcacca agggattatt gcgaaagtcg 120
 tgccgcaaaa agagctgaac gaacatgac tggtatgctat tctggcgcaa aaacaaaacc 180
 cgtttttatt aatcttagac ggtgtgaccg atccgcataa ccttggtgct tgtttgcgta 240
 ctgcagatgc ggcagggtg gatgcggtga ttgtaccgaa agataaatcg gcacagctta 300

- 12 -

cctcaaccgc tcgtaaagta gcttgcggtg cggcggaac cgtgccgtta attcgtgtta 360
ccaaccttgc tcgcacaatg cgagagctac aagagcaaca taatatctgg attgtcggca 420
cggcaggtga agcgacttcc ggtatttatac aggctaaatt aaccggtgct atcgct 476

<210> 17
<211> 1011
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 17
attgcgcaaa atgctaacag aattatcaaa atcaaagatg gcgaaattat tgcagataat 60
agttcatact gcaagaatag cctctcccc tcaacaaagc aggaaaggca aagtctaaac 120
tgcttgatgt cgctacgagg ctataaagaa tcttttgtga tggcattcag tatgatgcgt 180
gctcataaaa ttaggacggt tttgactatg ttaggtataa ttattggcat tgctgctgtc 240
gtatgtgtag tagcattagg agaaggaacc aaacataaag tcttgaatga atttagctct 300
ttaggtagca acacaataga tatttttcct ggtaaaaatt ggggagatac cgaagcatat 360
aaaattcaaa cgtaaataag caatgacgta aatttattac gccaacaacc ctatgtgaaa 420
ggtgcgactc cgaacttatac gttagaattg ccaatccgtt tcttaaataa aactgccaat 480
gcaacgataa atgggtgtag ccaagatttc tttatgttaa aaaactacaa attactaagt 540
ggcagatttt ttaaccaaca agatgtagat acttatcaag ctggtggcat aattgataaa 600
aaatcacgag atgtaatctt cggcacaaaa attgcagaaa gcaatatagt ttttatcggc 660
gatgtaccta tttcgattat cgggtgtgtt gagtccgcct cccaaacaac tgaagggcag 720
cgaaccacta tttggttacc gtacaacact atggctgctc gtttacgtaa ccaaccctat 780
tttcaacaaa ttacagtga gttacgagaa aattttgtac cagcagcagc cgataaggct 840
attgtggatt tattggcagc aaagcaatcc atatcatggc agataggatt tttttacttt 900
cagtagcagc aagttcttgc aatccttaaa tcgcactaca cagccctaac tttaatgatt 960
tcatttatcg cttttatttc gctggtagtt ggaggtatag gagttatgaa t 1011

<210> 18
<211> 650
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 18
tcgacgctga gcgtctttat atgggcaatg gtgaggggta gttttacctt ttgcataggg 60

- 13 -

tgtgcatatt acagatagaa agcaaaatag tcaaagagaa aatcggattt ttaaaaaata 120
 tctcataagc taaactaaat aaaccgaacc ggtttgatat aaggtaaact tatagaaatt 180
 tttcacgtct aaccatagca aaaaagcgat aaaactggta atttgactat tcgtatctga 240
 aaactattct tatttttaat ttaaacggga tgacaatgtt atttgcgatt ttagcaatgc 300
 tggcttatgc tgccgcatta ttatgggtta cccccacact cgtcaattta gaaaacaaaa 360
 ccggtgataa aaaaccgaat cttaaagcgg tttttggatt cggcttactt gccgtattct 420
 ttcacgcaat caatttatcg caagaattgg tgctgagcgt gctgagcgag ggcggtcaga 480
 atttctcact ttctaacgta aactcaatga tgagcttatt gctgacggct gtcgcaacac 540
 ttgccttacc gcgttgga aaaccatttggg ttccgttaat ggtgggttat accttcggca 600
 tttgtagcgt agcggcatcc gcatttgcca gcggttaactt tattaaaaat 650

<210> 19

<211> 620

<212> DNA

<213> *Actinobacillus pleuropneumoniae*

<400> 19

gcaatacctg cactcggggc gtcttttcggc gttgcgccgt ccggcacgag tacgtgaata 60
 tcacgttttt catagaaggc atccgcactg cctaattgtg cggatcttgc acgtaccacc 120
 atcattgccg cttgaatcga ttctttcatc acatcgcccta atgaaccggt aaatgagaat 180
 ttacctttac cgccgaccga agtggtttcg atggtagta aatcgccgcc gacttccgtc 240
 caagctaagc cggttacttc accgacacgg ttttggtgtt ccattttacc gtaatcaaaa 300
 cgttttacac ccaagtaatc ggcgatattg ctttcgggta ctgtaattga tttgactttt 360
 ttgtccaaca ccagagtttt caccgcttta cgacagatct tagcaatttc acgttcaaga 420
 ctacgcacac cagcttcacg agtgtagtaa cgaataatgc ttaaaatagc actatcttcg 480
 atagttaatt caccgcgttt taagccggtta ttttcttgct gtttggcaat taagtggcca 540
 cgggcaatgt gcattttctc atcttcggta taaccggaaa gacgaatcac ttccatacgg 600
 tcgagtaatg ccggcggaat 620

<210> 20

<211> 272

<212> DNA

<213> *Actinobacillus pleuropneumoniae*

<400> 20

- 14 -

agcgaagcta ccgctcgaag taaaagaaaa actagatagc gagtttaaaa agttaaagc 60
gatgccgcaa agttcttccg aagcgaccgt cgtaacgaggc tatatcgatt gggctcttaa 120
aatgccgttg aacaaaaaat caactgtgaa aaaagacttg gcgaaagcgc aagaaatttt 180
agacaaagat cactatgggt cggagcgtgt taaagagcgc attgtcgaat accttgcggt 240
acaaagccgg ttaaacaac ttaaaggccc ga 272

<210> 21

<211> 669

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 21

agtacctttt caaagcttgg gttgcttttg caaaccaaga ttggattagc gtaatctcat 60
tacttgaaag taagctctct gagttaagta aaaaagactt agatttatat ttgcctgagc 120
tattgcttgc tcgagcttac tgtcaattaa atgactttac ctctcacat aattgtttag 180
ttgcatttga gagacactct gctgcatttc cattgtctcg aatcgaaata gcacacctag 240
cacactctgc cggagcgcca ttgtctcgaa tcgaaatagc acacctagca tatgcaagac 300
gaaattatac aaaatgtatt gatcaactta ataatgctt tgctaaagaa cttgacaatc 360
tacctgcaga gagtttagag gaatatgctc tttccttact taaaggaaat aacactaagg 420
aatttgaaaa attagtagaa agttctctaa gtgagaagtt taaagatcga actttcttta 480
aaaaagaata tgtttccttt cttgctaaaa atcagttatg gaaaaaatta gttaaataatg 540
ctagcaattg ggcattacaa gataaagaaa aattcaatta tccattaatg cttgctcatt 600
atagattagg agatattgca tatgtttatc agaatcatat aaaaccgact gaagaacatc 660
cctatgaat 669

<210> 22

<211> 277

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 22

ggctttgcag tagcggaac gcaaatgta tcgtcggata aattaccgga aaatgtggcg 60
ccggcttata ccaaccgcga taaagatatc ggtaacattc cggtgacttt ccctcatcaa 120
ccgccgcttg ttccgcatag tattcgtggg ttacaagtaa ctaaaaatac caaccaatgt 180
ttaggttgcc atgcgcgga agtatcaagc acgacgggtg ctccgctgt gcctaaaacg 240

- 15 -

cattttatgg atcgagacgg taaattgacg gaaggaa

277

<210> 23

<211> 807

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 23

tggaagtgcac tcgtctgcgt gatacgccga tcttaacttt tatgaacaaa ctcgaccgtg 60
atatccgtga tccgatggag ttactagatg aagttgaaag cgtcctaaaa atccgttggtg 120
cgccgattac ttggccgatt ggttgccgga aattatttaa aggcgtctat catattgcaa 180
aagacgaaac ctatctttat caatccggtc aaggttcaac cattcaagaa gtacgtatcg 240
taaaaggctt gagcagccca gaacttgatg ctgcggctcg tgatgattta gccaaccagt 300
tacgtgaaga attagaactt gtacaagggtg catcaaacga atttgatcac gaagccttta 360
tcaacggcga actcacaccg gtattcttcg gtaccgcatt aggttaacttc ggtgtggatc 420
atttcctaga cggtttaacc gaatgggctc caaaaccgca agcacgtcaa accgatgtac 480
gtacggtcga atcaagcgag gaaaaattct ctggcttcgt gcttcctgtt aagatccaag 540
cgaatatggg ccgaaacac cttcaccgat tggcatttat gcgcgttggg ggaggcaaatt 600
accgaaacac ggtcttcaaa ctcaaaccac tacgtatcgc cataagatgt ctgcgatttc 660
cagatgcctt aacctttatg gcgggtgaac gtgcacatgc tcgaagaagc ttacgcgcgg 720
cctatattat cggtttacat aaccacggaa caatccaatt cggtgacacc ttcactcacg 780
gtgaagtgat gaaatttacc gccttcc 807

<210> 24

<211> 402

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 24

cacgcggtac ggatgtcatt ttacatttgc gtgaagcaga aaaagaattt ttaagcgaat 60
ggcgtttacg tgaaattatc ggtaaattatt cggatcacat cggcttaccg gttgaaatcc 120
aaaccaccga atatgatgaa gaaggcaaag caagcgggtca aaaatgggaa aaaattaaca 180
aagcgcaagc actttggact cgttcaaaaa ccgaaatttc agacgaggaa taccaagagt 240
tttataaaca ttttaagccac gattataatg actcgctcat ttgggcgcat aataaagtag 300
agggtaaaca agactatacc agcttgcttt atgtaccggc gaaagcacca tgggatctgt 360

- 16 -

tcaatcgtga tcaaaaacac ggcttaaaac tttatgacag cg

402

<210> 25
<211> 551
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 25
tatcttcgca tcggtgagcc gccatgttcg gttaaagcc ctactacca ttcgtcaata 60
cgatcagata ataacagcac ttcaatgcct ttcttattga acagttcaag gtgcgggcta 120
tttttcgceg ccacataact atcagcgggt aagaaataaa tcgctttctg accttcttct 180
attctgccga tataatccgc caaacttacc gtttggtcgc tagaatcagt ttgggtcgaa 240
gcaaaacgga ataatgacgc aacttggtgt ttattcgcaa aatcttcacc aacgccttct 300
tttaacacta aaccgaattc gttccagaag gtttggtatt tagcttgatc gtccttcgct 360
aatttttcca ataattgcaa tgcacgttta gttaatgccg cacgtagtga agcagtaact 420
ttattctctt gtaaaatctc acgtgaaacg ttgagcggca agtcattcgt gtctaataaa 480
ccccgcataa aacgtaggta attcggcata aacactttctg gcacggcca taataaatac 540
acgctgtaca t 551

<210> 26
<211> 281
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 26
cacttagccc ccaaattagc agttcctaaa aaaaagcctc cctcaaagga agtaaaaaaa 60
gcgctgaaa agatcatgaa aaaacatgag acaaagaaag atgtttctcc acaaaacaaa 120
agcagtcgta ctcagcagcc gatccaacaa ggaaatccaa atggtataaa tggaagcaaa 180
tcaacctatg gaaatgccaa agtcgatgcc tcccttggtg ctggttatgg caatgcaatg 240
cgagggccgt tgctctgata tttcagatga atctgatgat g 281

<210> 27
<211> 735
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 27
attatgaacc aattaaaaaa tgatcggttac ttaaagcgt tactacgtga accagttgat 60
atgacaccgg tatggatgat gcgtcaagcg gggcggttatc taccggaata taaagcgaca 120

- 17 -

```

cgtgcggaag ccggcgattt tatggcttta tgtcgcaatg cagatttagc ttgtgaagtg      180
acgttacagc cgctacgccc gctacgccgc tatgcattgg atgcggcgat tttattctcc      240
gatattttta ccgttcgga tgcaatgggc ttaggtttta gtttcggcgc ggggtgaaggg      300
cctaaatttg ctcgcccgat tgaaaataaa gcgcaggtgg acaacttacc gattccggat      360
ccggaaagcg aattacaata tgtgatgaat gcggtacgta ctattcgccg tgaattaaaa      420
ggcgaagtgc cgттаатсгг tttttcaggc agctcgtgga cattggcgac ttatatggtg      480
gaaggcggct caagcaaagc gttcaccaaa attaaaaaaa tgatgtatgc cgatccgaaa      540
attttacacg cattattaga taaattagcc gatagcgtga tcttatatct gaatgcacaa      600
attaaagccg gcgcgcaagc ggtgatggtg ttcgatactt ggggcggcgt gttggcgcat      660
aacgaatata aagagttctc gctacgttat atgcacaaaa tcgtggacgg tttaattcgt      720
gaaaacgaag gcaga                                           735

```

```

<210> 28
<211> 539
<212> DNA
<213> Actinobacillus pleuropneumoniae

```

```

<400> 28
tgcgtggtat ccacacgatg gaacacttat ttgccggctt atgccgtgat catttaaata      60
gtgaaagtgt agaaattatt gatatttcgc cgatggggtg ccgtaccggt ttctatatgt      120
cgттаатсгг tgcgccaagc gaagcggatg tggtttcggc gtggacaaaa tcgatggaag      180
atgcttttaa taaagtaccg gacgtgtcaa aaattccgga attaaacgaa tatcaatgcg      240
gctcttataa agagcattcg cttgaagaag cgcacaaat cgctcgtgat gtgttagcca      300
agggtatcgg cgtaaaccgt aacgaagatt tagcgcttga tgagaaatta ttaaatccat      360
aatccttcaa aaaggcgtaa tgtttattac gtctttttct tcttaaaaat atattttaat      420
ctttgacaga cgcttatggc gtcttttagt tttttcagga aagtaagatg ttcaacaaaa      480
tttttagttg gtttgaagca agagtggaaa cttaccccca agcaccgcg aaaacgccc      539

```

```

<210> 29
<211> 104
<212> DNA
<213> Actinobacillus pleuropneumoniae

```

```

<400> 29
cgcagtgtaa gtttttgccc gattgcacga tgtagaagaa gtgcgggttac tgatgaatcc      60

```

- 18 -

acgccgcctg ataaacctaa aatgacttcg tcatcgcccta cttg 104

<210> 30

<211> 1201

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 30

tagaaaaact ctgaagtcct tgagaatttc cgctcttcgc catagcctgt aacgcttggg 60

tcggcacgtg taataagctg ttggtcagtt tataacttag ctcgttaagg actttttcac 120

tatcttgtcc actggttaag gcaactaatg ctttcgctaa tagctcttga cgagtttgct 180

cggcattctg gcgataacgt ttaatcaaat cgctggattg ctggtgtttc agccattcaa 240

agaacgcttt acattcttca tccacaattt gtgccgcttg ttctgcagct tgttctcgtt 300

gcgccatatt acgttgaatg atatgttgta aatcatctac gctgtaagaa tataccgcat 360

ccaattcgcc ggcatttttcg tcaatatcgc gaggaacggc aatatcaatc aataacatcg 420

gatcaaaactg gcgttggttc tgtgcgattt ccaccatttc tttgctaate agcatatccg 480

gactgccggt agaactgata acgatatccg cttgggttaa accgatttgc aatgcgctta 540

atgataaaat ttgcatcggc gtgttttaaac gctccgctcg ctccgctaac gtttccgcac 600

gttgccggt acggttggtg atcataatgt ttttcgcgcc gtgctgaatt aaataacgcg 660

cgactaatte gatgggttcg ccggcaccga ccaacaagaa acgcaattta ccgaaattat 720

cgaaaatctg gcgtgcaaaa ccgcaagcgg cataagcgac cgataccgca cttgaaccga 780

tttccgtttc ggaacgcaca cgttttgccg tcgaaaagggt acgttggaac agacgggata 840

atttagtaga aatatggctg ttctgcgatt ggtaaaaatt ctgcctatat tgataagctt 900

gttttacctg gcctagaatt tgccgctcgc ccaagataag cgaatctaaa ccgcacgcta 960

ctcgcattaa atgacgagcg gcttccatat tttgtttgaa ataaatacat tcgcgtagtt 1020

cattatgttc aagttgatga atttcggcaa accattcaaa acattgttca cgccatgcga 1080

tgttatcttc atgttcttct cgcggcgtaa tttccgcatt atgaaaataa agctctgttc 1140

ggttacacgt tgaaagaatg acaacgcttt cagcaagtgc gcggggggtg aatttgctca 1200

a 1201

<210> 31

<211> 250

<212> DNA

<213> Actinobacillus pleuropneumoniae

- 19 -

<400> 31
agcaaagttt attccaacaa tcaaatctat tgattacgga ctattcatct attgcatttg 60
aaatggcatt tctaggaaaa caaacaatct attaccaatt tgataaagag gaatttagat 120
ctggaattca tacatatcaa caaggatact ttgaatacga gaaagatgga tttggtcctg 180
tagctgaaac attagatgat ttatttattc acctagataa attcgtaaac ggtgaaaatg 240
attcataaat 250

<210> 32
<211> 364
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 32
cgccacgctt atatacaaca accgccaccg tattggataa attcatactg cggtgtgctt 60
tacacattgg cactcggatt ttttgcgaca tcggtaaatt atccaaaatc gtcacgggga 120
taccacggct ttccggccca aacataagga agtcgcctaa ttcataactc acttcactat 180
gattcggttc gccttttagtt gtcagcgcaa atagacgttt tggcttggcg cgttctagaa 240
aatcttcaaa attcttatat ttttgaatat cgacaaatc gtggtaatcc aaacctgaac 300
gacgtagttt tttgtcatcc cagcgaagc ctaacggttc aatcatatgt aatctaaaac 360
cgca 364

<210> 33
<211> 486
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 33
cgcttggtaa gcgattgcc gtgcggctcg cataagtaac cttcccatat tgtgcttta 60
tgctgcttcg gtttcgcgat cgtttaatgc cgcctaacct aaatcgctta acgccaacc 120
gttgcgttta aataattctt ccacacgagg ccagttgttc gggcggctta cgtccattgc 180
gtttgaaagc gttgctaccg ttgcgttcg ttccatttta cctgatttta aataacgcgg 240
cactgtgtca ttgcattgg ttgatgcgat aaaacgttta attggtaaac ctaaggtttt 300
tgcgattaaa ccagcgggta agttaccgaa gttaccgctt ggtactgaaa ccactacatc 360
agaacgtttt gctttcggta attgtgctac cgcttcaaag taataacaaa cttgcgctaa 420
taaacggctg atattgattg agttttgcgg agttttaagc ccgatcgttt gacgtaatc 480
agcaat 486

- 20 -

<210> 34
<211> 241
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 34
attgtttccg atatccttga gttagtaa at cctgatttag cccatattca ttgtattcaa 60
ggcttaggcg ttggtgttgt tgatgc atgc acacaacgaa atataaagac tgctgtaacc 120
ttacatgatg cttggtggat ttgccctcgc caatttatga ttaaagctga tggtaagttc 180
tgatcatcaat ataaaattga taaaaatgaa tgtataaaat gtattggtag tacatcagaa 240
t 241

<210> 35
<211> 479
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 35
tactaaacga ggatttttca cttgcggacc ggcaagcgaa ataatacggc cggtaaagag 60
ttcgcctgta gtaaataatt taccgatagc aatcacatct tgataattta agtgccaaac 120
ttgtttgggc gcccctacgg gatcaacaaa gtggatatgc gtaccgacta aaccggcagg 180
atgaacaccg ctaaacgact taattgtgat accttcaatc gccggactta acgggatatt 240
gctgtccgcg tctttacata agtaaaccgg tttttgaccg ttaaataaac gggttaaaac 300
agttaaaccg tctttaaaat cggtttcgta ctcttttaaa accacttccg gatccgccgc 360
taacggattg gtatccattg cattgacaaa gattgatgac ggaatcgcg ccaatgcggg 420
aaccttactg aacggacgag tacggaatgc agtccataaa cccgattcga taagatttt 479

<210> 36
<211> 380
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 36
tccacttctt ccgctaccgc tgcagccggc acttcaattt cattttgtgc gattaaaccg 60
ttgattactt gggttttaac gcgtgcgggt actgcgtttt taagttcacg ttgcatattt 120
ttcttaattt ccgcacgtaa atcttctaca gtttttgctg aaccgaattt tttcacgaat 180
tcttcggtta attcaggtaa tacgatattt tctactttct taagtgtaat tgcgaatttc 240
gccgctttac cttttaagtt ttcagcgtgg tattcttcag ggaaagtaac atcgatatcg 300

- 21 -

aattgttcgc cggctttgtg accaacgata ccttctttaa aaccagggat catacgactt 360
tgacccattg ctaaagtga 380

<210> 37
<211> 498
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 37
tgcaaaacgt cgtgttcaag taggtttatt actttcaacc gtaatcggta ctaacgaatt 60
aaaagttgat gaaaaacgtg ttgaagaaac gattgcagaa atcgcttcag cttacgaaca 120
accggcggaa gttgttgctc attatgcgaa aaaccgtcaa ttaaccgaaa atatccgtaa 180
cgtagtggtta gaagagcaag cggttgaagt tgtacttgcg aaagcaaaag taactgaaaa 240
agcgacttct tttgatgaag taatggctca acaagctcaa ggctaattct caaacataaa 300
gctctccggt ttggagggct ttttaattagc attttataag cggttgattt taggaaaaaa 360
tttgcaaaaa tttctctaaa aatgaccgct ttctttttta caagaagaga atttagtcat 420
ggatttaaca tttactcaac agctccaaca atttattgcg gcccatccta ttttaatttt 480
tgcttggatt gccttagt 498

<210> 38
<211> 604
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 38
attatcagga agatgttgat tattatttaa tggcaaaacc aggaatgacg gggctttggc 60
aggttagtgg aagaaataat gttgattata agactcgagt atatttcgat gcttggtatg 120
taaaaaactg gtctcttttg aacgatattg ctattttatt taaaactatc aatgtattaa 180
ggagccgaga aggagcttat taatcctata gggctagagt aacttactat gcaatttgcc 240
ctttacttta taagccggct ggggtaaaat gtactacctt ttttagttct atgtcgccaa 300
aattgtgtgc gactttattt aaacatatat ttcttgaggt gatggcatat gccagtaatt 360
aaagttcgtg aaaatgaatc atttgacgtt gcattacgtc gtttcaaacg ctcttgcgaa 420
aaagcaggtt tattagcaga agttcgcgct cgtgaattct atgaaaaacc aactacaatt 480
cgtaaacgtg aaaaagcatc tttagctaaa cgtcacgcta aacgtaatgc tcgtgaaaat 540
gcacgtaaca ctcgtttata ctaattagca gtcttgctat ttaggcttaa attaactaaa 600

- 22 -

accg

604

<210> 39

<211> 410

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 39

cagccgagcc tatattgaat tagcggcaaa agtcgcttcg gagctatact ggcaagggtc 60

ggttatcccg tctgaaatta tgattcgca agtaaaataa gttttaataa ccacgaaaac 120

acaaagaaca caagcggtag aatttgcaga aaaatctgca aatcctaccg cttttttatt 180

agtacgattc gctggttgac tgctatttga tttggtttgt caggatatta tgttattgta 240

atgaaatggt agtgaattat ttttattaat ttgaaaggaa acaaaatgaa aataaaaaaa 300

cgttacattg cgctgttggt cttagggtgc gttatcagct atgcctggta tcaaaattat 360

caatgggaac agctgatgtt aagcgggtat tgtgaaaagg acggaagtta 410

<210> 40

<211> 330

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 40

ggttaagcct aaccgcttat taatgtcttt taatagctgt aaaatcgatt gtgtagtcgc 60

cggatctaata gcaactgtcg cttegtcaca taataaaaca tgcggatcac ttgccaacgc 120

acgggcaatt gcgacacgtt gcttctgacc gccggataaa ttgctcggtat aaacatcttt 180

acgttcgggt aagccgacca attcaatcaa ttcgtttact ttcttctcga tctgatcttt 240

cggcgtattg ctcaacgtaa gcggtaatgc gatattttca tataccgtat gtgatgcaa 300

caaattaaag tgctggaaaa tcatcgcaat 330

<210> 41

<211> 952

<212> DNA

<213> Actinobacillus pleuropneumoniae

<220>

<221> misc_feature

<222> (528)..(528)

<223> n is a, c, g, or t

<400> 41

agtaacgctt ccatttttgc tgaaaaatca cgaccaagaa taatctcatc accgtgcaaa 60

- 23 -

acactactta cggcatggta tcttgcccat ttttgcttta attcgggact ttcgcataac 120
ccgtcgatga acgcatcacc aacttttttc ccgtccataa aagcggaaag ggtttcattt 180
tggtgcataa taaactccga ttgaatctta aatctgttgc attagcggat tgacctttgc 240
atcaatcgct tctcttgctc taaagatacg cgaacgaacc gtaccgacgg gacattgcat 300
gacttccgca atttcttcat aacttaaacc ttccaactca cgcaaagtaa ttgccgtttt 360
gagttcttca ggtaaatttt caatcgtgct aaaaacgaca cgttttaatt cttcggatag 420
caccacattt tccggtgtat cactctcacg aagttgacct ccaacatcaa agctttccgc 480
atcttccgcc aaaatatctt ctttaggagg acgtcttccc aaagcggnta aatgattttt 540
agcagtgttc accgcaatac gataaagcca cgtataaaaag gcgctctctc cacggaaaga 600
ctctaataga cgatacgctt taataaaaga ttcttgcaca atatccggaa tatcatcacg 660
tgaaacatag cgagttaata aacctgccac tctattctga taacgtacga cgagtaaatt 720
aaatgctttt ttatcacctt tctgtgcacg ttcaaccaat tcttgatcgg ctaccagctc 780
actcatctat ttgcgttctc ctaatctatt tcgcatattc cttattgttc tcattccgta 840
catccttttag tgtgtaacaa aaatgaaaag ttcatataaa gaataaatta ctcaattatt 900
tacaaatact ttaataaaat tcaataacaa gactaaggat gctacaaata tt 952

<210> 42

<211> 1196

<212> DNA

<213> *Actinobacillus pleuropneumoniae*

<400> 42

aatattttta tgagcgtatt aaagatgaag acaccaatcc gctatccgaa caagagctaa 60
atcaatttgc gatggcatta cgcgtcgaat tacaaaataa accgaatgat gccaaaggct 120
ggtttatgtt aggtcaaata cgcgtcgaat aagatgacgg gcaattagca ctggaaagct 180
acgaaaaagc cagcaaactg gacccgaaaa atctgcaata taaaggcagc tacgctcaag 240
tgctgatgtt ctcgcaagat caagcggata aggacagagg taaagcgggtg ctaaaagaaa 300
ttttacgtga agatcatacc aatttagatg cgctcagctt actggctttc agttcttttg 360
aagaacaaga ctataaaatg gcggcaatga cttggggcat gatgctaaaa ctgattcctg 420
aaggcgaacc gcgccgcgct acagtagaaa aaagtatcaa tatggcaatg tcgatgttgc 480
aagagcaaga aagcaaacaa ccggctaaag cggaagagaa aaaataataa catttttagcg 540
aagctaaaaa ctgatgtcgg gcgggtttat acccgcccta aaattgcaaa aggataaata 600

```
<210> 43
<211> 601
<212> DNA
<213> Actinobacillus pleuropneumoniae
```

```
<210> 44
<211> 266
<212> DNA
<213> Actinobacillus pleuropneumoniae
```

<400> 44

- 25 -

taaaaataac tacggtccga tgttacgtgc tgcgtagag aagatcgaga aggaagggtta 60
 agaaaatggg tttaaaaaat ctttttgaaa agatggaacc tgcgtttcac aaagggtggaa 120
 aatatgagaa atggtacacg ctttttgaag cgacatatat cattctctat acaccaggta 180
 cagtgactcg taaagattca cacgtacgtg atgcgttaga ttctaaacgt atgatgatta 240
 tcgtatgggt agcgttattc ccggca 266

<210> 45
 <211> 1065
 <212> DNA
 <213> Actinobacillus pleuropneumoniae

<400> 45
 aactaaggat agatatgtta cagaataaga aaattgcagc agttattcca acttttagag 60
 tgcttgctca gattgaaacc gttttgaaaa gaatacccga gtattttgat atgatttatg 120
 tcgtggatga taaatgtgat caaggtagtg gtaaatttgt tcaagaacat attatggatt 180
 ctcgagtaaa agtgcttttt catgaagtga atcaagggtg tggaggagct gttattactg 240
 gttataaaca agcaattatc gatcagatgg atgtagtggt taaaattgat ggtgataacc 300
 aaatggatcc ttatttggtt gaaaaattta ttttaccat tgtaaatgga gatgcagatt 360
 atacaaaagg aaatcgattc tttaaccttt cagacgtagc ggatatgccg aaagtgaggt 420
 tttttggtaa tattgctctt tcttttttaa ccaaagcatc atctgggttat tggaaaattt 480
 ttgatccgac aaatgggttat acggcaatta gtgttaaagt actaaaaatg ttggcttttag 540
 acaagattca aaagcgttac ttttttgaaa gtgatataat attccgattg aatatgatct 600
 cagctaaagt attagatgtg ccaatgggtg cagtatatgg agatgaagta tccaatttaa 660
 aaattagcaa aatattcttt ccatttctaa aaggaaattt atctaatttt tcaaagagaa 720
 ttttctataa atatttcttg caagatttta atgttgcttc tgttgaatta gtatttggtt 780
 cagtaatgtc attattcgga atattatttg gactatataa ttggattgct aatgcaatta 840
 ataatataga aacaccaaca ggaaccatta tgatttctgc attgtttatt ttagtaggaa 900
 ttcatttatt actctctttt atatcttatg atgtaaataa ttatccaacg gaatcaatta 960
 gtaaaaattt agatgaataa tcccatttgt tctgttattg tttgttatga accaactaag 1020
 aaaatatttt ttttaatcaa ctctctaatt aagcagaatg tatat 1065

<210> 46
 <211> 155

- 26 -

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 46

ggaaggctta aaacagctgt ttcaggggaag tcaccccgctc aaaaaactga tacgaggcgt 60
agggttatcc gcaaccaatc aactaccggt attaaagaaa ttattgattg ctcaggcggt 120
gggtatttga cttgtctggt ttttagtcag ataataat 155

<210> 47

<211> 771

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 47

tttttggcgt tttagaaaag tcgcaaattt ttccggctct ttttgttgat aggcgaaagt 60
catcgtggac tcttttaata agaaagtgga agatttgctc gaattacaat caatcgaagt 120
ttatttgtca aaataaaaaa atgaaatctt tgaactactc cacaaattaa ttgagcaagc 180
ggttaaattt acaaattttt ttgcaaattc aaccgctttc cattagaatt ataagacttt 240
tggggctgat tctggattcg acgggattag cgaagtccaa ggtgcacgct gaggtgcggt 300
aggcctcgta aacaaaccgc aaaaaaatag tcgcaaacga cgaacaatac gctttagcag 360
cttaataacc tgctcatagc cttatcgctt cagcttccgc tcgtaagacg agggcaacga 420
taagtcaccc aaaacgagat cgtgtggacg ccgccgtttg aggatcgaaa cactaaattg 480
aatcaaacta gcttatttct tgcgtgtctg tccgctggag gtaagtgaat ttaaagacca 540
gactaaacgg actaaacgtg tagtgctgaa gatggagtaa tttcggacgg gggttcaaat 600
ccccccagct ccaccaaatt tgtatacttt taatagggtta tttaaatga aattccacca 660
aaaactaaat agaactgcc aactgcagt ggctattgca cttagtagtt ttggtgtatt 720
aggatatgtc tcattagata atgtcactca atctattgaa aatataagaa t 771

<210> 48

<211> 313

<212> DNA

<213> Actinobacillus pleuropneumoniae

<400> 48

ggtcggcgat aagatcgtaa gtgtcgggtc ggataacgat gagattgaag atgttatcgg 60
ctggcggtta gatgatgttg tcgataagat catacgtact aatgggtacta aagtcgggtt 120
cgaaattgaa ccggaaaaag gcggtgaaac gaaagttatc actttgggtc gagataaagt 180

- 27 -

ccgtttagaa gacagtgcgg cgaaattaac cgttgataaa attaacggta aaaatgtcgc 240
 ggtaattaaa atttcaacgt ttacatcgg ttgaccaat gatgtgcgta aattattaga 300
 tgaaatgtac act 313

<210> 49
 <211> 225
 <212> DNA
 <213> Actinobacillus pleuropneumoniae

<400> 49
 ttcttaattt caggccattt tttatcttta agatagagat taattacatc gtttttaaca 60
 cgttgttccc atagctgatt ggcttcttca accgttgccg gaaacgccgc cttttcacga 120
 tcattttcga ttgatccga cccttttaaa ttcggctctt tatctaataa agacaacgca 180
 tacttataac gtccataacc gacgtttggt cattaaatca tagat 225

<210> 50
 <211> 1045
 <212> DNA
 <213> Actinobacillus pleuropneumoniae

<400> 50
 attcgtgccg cattagtga atacgatccg aaaaatgccg aaagctataa ccaaaatgct 60
 aaagtttatg cagaaaaagt aaaagcaatt gccgaaccgt tacgccaacg tctatccgtt 120
 attccggaag cacaacgttg gttagtaacc agtgaagggt cattcagttt ttagcacag 180
 gactatcaat taaaagagct ttatctctgg gcaattaatg ctgaagagca aggctcgccg 240
 caacaagtga aaaaagtaat tgacgggtgta aaagccaaca atatccctgt tgttttcagc 300
 gaaagcaccg tatcggataa accggctaaa caagttgcta aagaaaccgg tgcattatc 360
 ggcggtgtgt tatatgttga ttcactttca actaaggatg gtgctgttcc aacttattta 420
 gatctattaa aagtcactat aagtacaatt gtggacgggt ttgaaaaaag taaaaataa 480
 catggtatcc attcctactt ctatttccgt tgaaaagcta agtgagctaa gtgtccgtta 540
 taataacggg catttagcct tatatgacgt atccttccaa ctgcaaaacg gtacgatttg 600
 cgccctaatac ggcgtaaacg gcggcggtta atccacacta tttaaaagtt taatgggatt 660
 agttaaacct caaacggta caattctgtt aaaccgaatg ccgattcaac aagcattgaa 720
 acaaaatctg gtgtcttatg taccgcaaag tgaagagggtc gattggcaat ttccggtttc 780
 cgtttacgat gtcgttatga tgggacgtta cggttatatg ggattgctac gccgtccttc 840

- 28 -

atctcttgat aaacaaaaag tgatgcaagc gatggaacga gtggatattt gccacttgca 900
gcatcgccaa atcgggtgaac ttccggcgcg gcagaaaaaa cgcgtgtttc ttgctcgagc 960
attagcgcaa gaaagccaaa ttattttgct tgacgagccg tttaccgggtg ttgatgtaaa 1020
aaccgaaaat gccattggtg gaatt 1045

<210> 51
<211> 263
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 51
tttttagata gcgtgaaaaa cttcttctct aacttaggta aacactaaag attaaaaagg 60
cttagcgaat ttgctaagcc ttttatttta ggcatagtag aaaaaagggt tggtaaaaag 120
tggtttaaag ctttatagta caaggcttta acctaccttt tgaaatatga ataaaaactt 180
gccctttttg tcaatcttcc aaacacaaaa gtatggctta aaaataagct tcaacgttat 240
aatgttcag cttgcaataa aat 263

<210> 52
<211> 1195
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 52
cttccgatga tacggaaatt ttagtttttt taactcaaga tgctttattt gcaagttcag 60
attctctaga agaattaata aaacctttcc aagatcctga agtaggggct gtttatggta 120
ggcagttacc tcacaaagat gcgactctat tagctgcca tgccagggtta tttaattatc 180
ctcctaaaag tataattaag tcgaaagaga gtatttcgga gttaggatta aaaacagcat 240
ttatctctaa ttcttttgcc gcataccgct gttctatttt tgaagaactc ggagggtttc 300
ctgagaaaaac gattttagcg gaagatatgt acttggctgc taagataatc ttgaatgggt 360
ataaaattgt ttataatgcg gaggcaaaag tctatcattc ccataactat tctttgatcc 420
aagagtttca gagatatttt gatactggag tattccaaaa agagcaatct tggattagaa 480
aagaatttgg tgaagcaaat aatgagggtg aaaagtttgt atgttctgag attaagtatt 540
tattgaagaa taatttttta ctattgtcga aagctatatt tcacactatg ttttaagtttt 600
tagggtttaa attaggtttg aattatgaga aattacctag atggttatgt ataaaattta 660
gtatgcataa gaactattgg aaataaatca tgaaaaggca gatattatct aaatatacgt 720

- 29 -

tagctataag tgatttttatt agtttttctc tatcatttat tctatcttta gtattattaa 780
attatttcaat tgagagggtt gatgcttata tcccacttga tcaagttaga gaaagaatga 840
ttatccactt atcggttaggt tttatagggt ttatatgggt ttggattagg cttcgccact 900
atacttatcg taaacctttt ggtttgaact aaaagaagtg atcagaacac ttattattct 960
tgctatattg agctagctac tatagccttt tcaaagcttt atttttctcg ctattatggg 1020
gtttaacttg ggggtgtaca ttcttcttg ttctattgt tcgtatttaa ctaaaaaaat 1080
cttaattgat acgggactat atattaagaa tacagtatta ttggtggagg gaataatgcg 1140
attgatgcct ataaagcctt aactagtgag tcttatttag ggtaaaagt aaaat 1195

<210> 53
<211> 288
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 53
ggatctttca ttacctttat caccataccg ctaccatctt cgagtaacca agagaagcat 60
ccgatttcgg atcataagca ccgatacgaa cttgttcgac taaaacaacg ctatcacgaa 120
cgggatcgta agcgattaat gccgcgctg cccctataat cagtaattca cgcacgattt 180
caccgctcat ttcaccggag aatagcttat gtcggaaata ctttttcttt aattcaaaat 240
gccctttata aacggtttct tctttaatca tgttgaagat actgttga 288

<210> 54
<211> 290
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 54
gcggacaata caatctctc cattgtctc ggcttcattc tacactataa tccgttcaat 60
ccggtgcaac gcacggctta taagaggaac gccaatatat tctggtacac gttgtcagcc 120
gatatcaagc ctatcaatgg gtgtgtgaag gcaaaatcga taatgttatc gcagtggctg 180
gtttacaatg gttacaactt aattatcaaa aatatcgagt gtaatgagcg ttttccgata 240
acgacgaata tattttgccc tctttaatga gggcaaattt tttgaagtat 290

<210> 55
<211> 47
<212> DNA
<213> Actinobacillus pleuropneumoniae

- 30 -

<400> 55
cgctcatcac caaacacttg aggttctaag agttttacat ccggaat 47

<210> 56
<211> 241
<212> DNA
<213> Actinobacillus pleuropneumoniae

<400> 56
cgcacctaga tatcgggata cgcgcggtca attagggatc tataccgaaa cgggtttatt 60
atcagttcaa aataacgtat taccgcaact tggtaaaaag taatcttgat ctaatgcttt 120
agaaaaactta gaattaatca aaagccccat agtttatgct ttggggcttt aattttttca 180
tcagttttta aattaagcgg tcaaaaatta agaatgtttt gcaaataaaa ttagttgaaa 240
t 241

<210> 57
<211> 19
<212> DNA
<213> artificial sequence

<220>
<223> synthetic primer

<400> 57
cgactacaac ctcaagcta 19

<210> 58
<211> 18
<212> DNA
<213> artificial sequence

<220>
<223> synthetic primer

<400> 58
cgaccattct aaccaagc 18

<210> 59
<211> 28
<212> DNA
<213> artificial sequence

<220>
<223> synthetic primer

<400> 59
cgccatgtcg accattctaa ccaagctt 28

- 31 -

<210> 60
<211> 27
<212> DNA
<213> artificial sequence

<220>
<223> synthetic primer

<400> 60
cgcctagtcg actacaacct caagctt

27

<210> 61
<211> 9
<212> DNA
<213> artificial sequence

<220>
<223> synthetic primer

<400> 61
gtcgaccct

9

<210> 62
<211> 9
<212> DNA
<213> artificial sequence

<220>
<223> synthetic oligonucleotide

<400> 62
gtcgacagg

9

<210> 63
<211> 19
<212> DNA
<213> artificial sequence

<220>
<223> synthetic primer

<400> 63
gacaagatgt gtatccacc

19